Page last updated: 2024-12-06

tirofiban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tirofiban is a non-peptide, small molecule, potent and reversible inhibitor of platelet aggregation that binds to the fibrinogen receptor glycoprotein IIb/IIIa on platelets. It is used clinically to prevent and treat acute coronary syndromes, such as unstable angina and non-ST-segment elevation myocardial infarction. Tirofiban is administered intravenously and has a rapid onset of action. Its mechanism of action involves the inhibition of platelet aggregation by blocking the binding of fibrinogen to the glycoprotein IIb/IIIa receptor, which is necessary for platelet activation and aggregation. Tirofiban is a highly effective antiplatelet agent that has been shown to reduce the risk of adverse cardiovascular events in patients with acute coronary syndromes. Its importance lies in its ability to rapidly inhibit platelet activation and reduce the risk of thrombotic events. Tirofiban is studied extensively to understand its mechanism of action, efficacy, safety, and potential for use in various clinical settings. Research focuses on investigating its role in preventing and treating cardiovascular diseases, optimizing its dosage and administration, and exploring its potential interactions with other medications.'

Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID60947
CHEMBL ID916
CHEBI ID9605
SCHEMBL ID3685
MeSH IDM0211213

Synonyms (59)

Synonym
BIDD:GT0363
ggx234si5h ,
unii-ggx234si5h
tirofibanum
n-(butylsulfonyl)-o-(4-piperidin-4-ylbutyl)-l-tyrosine
CHEBI:9605 ,
144494-65-5
tirofiban
C07965
n-(butylsulfonyl)-o-(4-(4-piperidyl)butyl)-l-tyrosine
DB00775
(2s)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
n-(butylsulfonyl)-o-[4-(4-piperidinyl)butyl]-l-tyrosine
tirofiban [inn:ban]
l-tyrosine, n-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-
hsdb 7323
CHEMBL916
agrastat
D08607
agrastat (tn)
tirofiban (inn)
bdbm50004058
AKOS015894972
S3085
gtpl6586
tirofiban hydrochloride (monohydrate)
tirofiban [mi]
tirofiban [inn]
tirofiban [vandf]
tirofiban [hsdb]
tirofiban [who-dd]
HY-17369B
SCHEMBL3685
DTXSID20162730 ,
(2s)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
J-524973
mfcd05237246
(s)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid
tirofiban, >=98.5% (hplc)
mk383
l700462
n-(n-butanesulfonyl)-o-(4-(4-piperidinyl)-butyl)-(s)-tyrosine
NCGC00263584-02
COKMIXFXJJXBQG-NRFANRHFSA-N
BCP06642
Q415366
l700462;mk383
AS-35267
BRD-K37872686-311-01-6
l-tyrosine, n-(butylsulfonyl)-o-[4-(4-piperidinyl)butyl]-
NCGC00263584-05
(s)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoicacid
n-(butylsulfonyl)-4-
n-(butylsulfonyl)-o-
b01ac17
2-s-(n-butylsulfonylamino)-3
(2s)-2-(butylsulfonylamino)-3-(4-(4-piperidin-4-ylbutoxy)phenyl)propanoic acid
dtxcid7085221
EN300-20599904

Research Excerpts

Overview

Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation. It is a potential adjunctive antithrombotic treatment in patients with acute coronary syndromes (ACS) or high-risk percutaneous coronary interventions (PCI)

ExcerptReferenceRelevance
"Tirofiban appears to be a safe and alternative during the stent-assisted coiling of ruptured intracranial aneurysms."( Safety and efficacy of intravenous tirofiban for stent-assisted coiling in acutely ruptured intracranial aneurysms: A single center experience.
Chen, X; Feng, Y; Jia, C; Ma, Y; Zhang, T; Zhao, W, 2022
)
1.72
"Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic treatment in patients with acute coronary syndromes (ACS) or high-risk percutaneous coronary interventions (PCI). "( Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.
Gurbel, PA; Heramvand, N; Jung, C; Karathanos, A; Kelm, M; Masyuk, M; Muessig, JM; Nia, AM; Polzin, A; Tantry, US; Valgimigli, M, 2022
)
2.4
"Tirofiban is a safe addition to SOC and may be an effective strategy to prevent early mBTTS thrombosis."( Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D, 2022
)
1.44
"Tirofiban is a highly selective nonpeptide antagonist of glycoprotein IIb/IIIa receptor, which reversibly inhibits platelet aggregation. "( Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial.
Bai, Y; Cao, W; Chang, M; Chen, S; Dai, W; Deng, W; Du, J; Fu, X; Ge, H; Guo, F; Guo, Z; Hong, Y; Hu, J; Hu, W; Hu, Z; Huang, C; Huang, J; Huang, W; Huang, X; Jiang, S; Jin, Y; Jin, Z; Ju, D; Ke, Y; Kong, W; Lei, B; Li, F; Li, H; Li, J; Li, L; Li, R; Liu, S; Liu, T; Liu, W; Long, C; Lu, M; Luo, J; Luo, S; Luo, W; Luo, X; Miao, J; Nogueira, RG; Pan, C; Peng, D; Pu, J; Qi, L; Qiu, Z; Sang, H; Saver, JL; Shi, Z; Song, B; Song, J; Sun, D; Sun, Y; Tian, Y; Tian, Z; Wan, Y; Wang, J; Wang, L; Wang, S; Wang, T; Wang, Y; Wei, L; Wen, C; Wen, H; Wu, D; Wu, J; Wu, Y; Xu, X; Yan, Z; Yang, J; Yang, Q; Yang, S; Yu, Y; Yuan, G; Yuan, J; Yuan, Z; Yue, C; Zeng, G; Zeng, H; Zhang, G; Zhang, J; Zhang, M; Zhang, S; Zhao, W; Zheng, B; Zheng, C; Zhou, P; Zhou, Z; Zhu, X; Zi, W, 2022
)
2.48
"Tirofiban is a glycoprotein IIb/IIIa receptor inhibitor that has been shown to be effective in the treatment of acute coronary syndromes. "( RESCUE BT 2, a multicenter, randomized, double-blind, double-dummy trial of intravenous tirofiban in acute ischemic stroke: Study rationale and design.
Hu, J; Huang, J; Kong, W; Li, F; Li, L; Liu, S; Luo, W; Nogueira, RG; Qiu, Z; Sang, H; Saver, JL; Song, J; Tian, Y; Yang, J; Yang, Q; Zi, W, 2023
)
2.58
"Tirofiban is a novel antiplatelet agent which is now widely empirically used in acute ischemic stroke (AIS)."( Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion.
Fei, Y; Lin, S; Lin, Y; Pan, X; Xu, M; Yang, J; Zou, J, 2022
)
1.81
"Tirofiban is a selective and rapidly activated antagonist of the platelets nonpeptide glycoprotein IIb/IIIa receptors that can reversibly suppress platelet aggregation."( Safety and efficacy of tirofiban in the management of stroke: A systematic review and meta-analysis of randomized controlled trials.
Al-Jebur, MS; Al-Salihi, MM; Al-Salihi, Y; Ayyad, A; Kasab, SA; Kass-Hout, T; Morsi, RZ; Saha, R; Spiotta, AM, 2023
)
1.94
"Tirofiban is a small non-peptide ligand-mimetic Glycoprotein (GP) IIb/IIIa inhibitor which can reversibly bind to the arginine-glycine-aspartic acid (RGD) recognition site of GP IIb/IIIa to prevent platelet aggregation. "( Tirofiban-induced thrombocytopenia.
Wang, J; Zou, D, 2023
)
3.8
"Tirofiban is a GP IIb/IIIa antagonist, other drugs in this class have been documented to induce thrombocytopenia as well, but rates for tirofiban appear to be the highest, the reason is unclear."( An Unusual Case of Drug-Induced Thrombocytopenia.
Khan, A; Sawalha, K; Wang, S,
)
0.85
" Tirofiban is a glycoprotein IIb/IIIa receptor antagonist that is widely used clinically. "( Effects of Tirofiban on Random Skin Flap Survival in Rats.
Chen, T; Cheng, L; Feng, Z; Li, H; Li, Z; Lin, D, 2018
)
1.78
"Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi, which contribute to the major atherosclerotic complications in the development, progression, and resolution of ischemic stroke. "( Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.
Huo, X; Miao, Z; Wang, Y; Yang, M, 2019
)
2.21
"Tirofiban is a fibrinogen receptor antagonist, generated using the tripeptide Arg-Gly-Asp (RGD) as a template. "( Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells.
Bisogni, R; Corcione, N; D'Angelillo, A; D'Arrigo, P; Ferraro, P; Giordano, A; Messina, S; Pepino, P; Polimeno, M; Romano, MF; Romano, S,
)
3.02
"Tirofiban is a small molecule, nonpeptide tyrosine derivative. "( Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.
Valgimigli, M; van 't Hof, AW, 2009
)
2.02
"Tirofiban is a small-molecule glycoprotein IIb/IIIa receptor inhibitor. "( Tirofiban for myocardial infarction.
Juwana, YB; Ottervanger, JP; Suryapranata, H; van 't Hof, AW, 2010
)
3.25
"Tirofiban is a glycoprotein IIb/IIIa inhibitor that prevents platelet aggregation and helps prevent thrombosis."( Heparin versus tirofiban in microvascular anastomosis: randomized controlled trial in a rat model.
Dziegielewski, P; Fu Zhu, L; Harris, J; Seikaly, H; Singh, P, 2011
)
1.44
"Tirofiban is a nonpeptide tyrosine derivative that together with eptifibatide (both small molecules) and abciximam belongs to the group of glycoprotein IIb/IIIa inhibitors. "( Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.
Cardenal, R; Diaz, JF; Gomez-Manchero, A; Sanchez-Gonzalez, C, 2011
)
2.12
"Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. "( Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.
Fiebach, JB; Hamann, G; Hennerici, MG; Junghans, U; Röther, J; Schneider, D; Seitz, RJ; Siebler, M; Villringer, A; von Reutern, GM; Witte, OW, 2011
)
2.21
"Tirofiban is a glycoprotein (GP) IIb/IIIa receptor antagonist used in the treatment of acute coronary syndrome (ACS). "( Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
Akpınar, TS; Besısık, SK; Elcioglu, OC; Ozkok, A; Sezer, M; Tufan, F; Umman, S, 2012
)
2.04
"Tirofiban is a safe and effective agent in combination with heparin and aspirin in the setting of an acute coronary syndrome."( Tirofiban-associated acute thrombocytopenia.
Köprülü, D; Tuhta, AG; Yeşildağ, O, 2006
)
2.5
"Tirofiban is a small, synthetic non-peptide, competitive GP IIb/IIIa antagonist with high specificity and high affinity for the GP IIb/IIIa receptor."( Current strategies with high-dose tirofiban.
Mukherjee, D; Roffi, M, 2007
)
1.34
"Tirofiban is a potent and specific fib receptor antagonist, used in the treatment of unstable angina."( The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
Jagroop, IA; Mikhailidis, DP, 2008
)
1.43
"Tirofiban (Aggrastat) is a reversible, nonpeptide inhibitor of platelet glycoprotein II/IIIa receptors. "( Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons.
Anderson, HL; Edmunds, LH; Gikakis, N; Gorman, JH; Gould, RJ; Hiramatsu, Y; Marcinkiewicz, C; Niewiarowski, S, 1997
)
3.18
"Tirofiban is a highly selective, short-acting inhibitor of fibrinogen binding to platelet glycoprotein (GP) IIb/IIIa that inhibits ex vivo platelet aggregation in response to a variety of agonists."( Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban
, 1997
)
1.26
"Tirofiban is a highly selective, short-acting inhibitor of fibrinogen binding to platelet glycoprotein IIb/IIIa. "( Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Cohen, DJ; Deckelbaum, LI; Gibson, CM; Goel, M; Harris, KE; King, SB; Piana, RN, 1998
)
1.96
"Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. "( Tirofiban. A review of its use in acute coronary syndromes.
Goa, KL; McClellan, KJ, 1998
)
3.19
"Tirofiban appeared to be a safe adjunctive therapy to coronary stenting."( Tirofiban and intracoronary stenting: evaluation of a new pharmacologic regimen.
Amidon, JB; Amidon, TM; Benson, JM; Coffler, D, 1999
)
2.47
"Tirofiban is a potent, synthetic, non-peptide and specific glycoprotein IIb/IIIa receptor inhibitor."( The role of tirofiban in acute coronary syndromes.
Collinson, J; Flather, M; Gomma, A; Purcell, H, 2000
)
1.41
"Tirofiban is a low molecular, intravenously administered GP-receptor antagonist, which in combination with unfractionated heparin in several controlled studies has been shown to decrease morbidity and mortality in patients with unstable angina pectoris and non-Q-wave infarction and, in patients subsequently undergoing percutaneous coronary intervention."( [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
Husted, SE; Rasmussen, S, 2001
)
1.94
"Tirofiban is a selective GP IIb/IIIa antagonist whereas abciximab has additional anti-inflammatory actions, which may contribute to its superiority."( ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET).
Doggrell, SA, 2001
)
1.31
"Tirofiban is a nonpeptide tyrosine derivative that antagonises platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptors. "( Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Kondo, K; Umemura, K, 2002
)
2.05

Effects

Tirofiban has been used historically as a bridge to platelet inhibition with clopidogrel in ST-segment myocardial infarction (STEMI) during percutaneous coronary intervention (PCI) to prevent stent thrombosis. The use of tiroFiban after intravenous thrombolysis (IVT) is controversial.

ExcerptReferenceRelevance
"Tirofiban has an elimination half-life of 2 h."( Extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation.
Chew, D; Gruendel, M; Jurmann, M; Koster, A; Kuppe, H; Merkle, F; Oertel, R, 2004
)
1.29
"Tirofiban has shown promising results in reducing delayed cerebral ischemia in retrospective studies."( Phase 1/2a Trial of ISPASM.
Allan, L; Hasan, D; Piscopo, A; Ryan, E; Samaniego, EA; Torner, JC; Zanaty, M, 2021
)
1.34
"Tirofiban has been used historically as a bridge to platelet inhibition with clopidogrel in ST-segment myocardial infarction (STEMI) during percutaneous coronary intervention (PCI) to prevent stent thrombosis. "( Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Chilbert, MR; Denny, O; Mills, K; Woodruff, AE, 2022
)
2.39
"Tirofiban has been approved for the treatment of acute coronary syndrome. "( Safety Profile and Complication Rates in Emergency Off-label Use of Tirofiban in Interventional Neuroradiology : An Observational Dual Center Study.
Altmann, S; Brockmann, C; Brockmann, MA; Dillinger, D; Kerz, T; Maus, V; Mpotsaris, A; Othman, AE; Ringel, F; Spreer, A; Waldeck, S, 2023
)
2.59
"Tirofiban has been used as a rescue when thrombectomy is not successful in endovascular therapy (EVT) for acute ischemic stroke (AIS), but the use of tirofiban after intravenous thrombolysis (IVT) is controversial. "( Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.
He, ZF; Hou, MM; Li, XY; Liu, XL; Ren, G; Shi, H; Sun, B, 2023
)
3.8
"Tirofiban has been used as a single monotherapy bridge given its safety profile and controlled platelet inhibition."( Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study.
Allan, L; Byer, S; Hasan, D; Ishii, D; Limaye, K; Nakagawa, D; Ortega-Gutiérrez, S; Osorno-Cruz, C; Roa, JA; Samaniego, EA; Torner, J; Yongjun, L; Zanaty, M, 2020
)
2.72
"Tirofiban has been used for the treatment of thromboembolism of ruptured aneurysms with a stent."( The safety and efficacy of low-dosage tirofiban for stent-assisted coiling of ruptured intracranial aneurysms.
Fang, Y; He, X; Hong, B; Huang, Q; Liu, J; Xu, Y; Yan, Y, 2021
)
1.61
"Tirofiban has been shown to improve ST-resolution, to decrease infarct size (IS) and to reduce incidence of major adverse cardiac and cerebrovascular events (MACCE)."( Safety and efficacy of Tirofiban in STEMI-patients.
Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Mourikis, P; Naguib, D; Pöhl, M; Polzin, A; Schulze, V; Wolff, G; Zako, S; Zeus, T, 2019
)
1.55
"Tirofiban has been widely used as an adjunctive pharmacologic agent for revascularization in patients undergoing percutaneous coronary intervention, and the outcomes appear attractive. "( Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis.
Li, L; Liu, Y; Su, Q, 2014
)
2.1
"Tirofiban has shown benefit in a wide range of patients presenting with acute coronary syndromes."( A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.
Adgey, AA; Belardi, JA; Bunt, T; Herrmann, HC; Juergens, CP; Levy, RD; Macaya, C; Menten, J; Meyer, BJ; Soler-Soler, J; Tarnesby, G; White, HD, 2002
)
1.3
"Tirofiban has an elimination half-life of 2 h."( Extracorporeal elimination of large concentrations of tirofiban by zero-balanced ultrafiltration during cardiopulmonary bypass: an in vitro investigation.
Chew, D; Gruendel, M; Jurmann, M; Koster, A; Kuppe, H; Merkle, F; Oertel, R, 2004
)
1.29
"Tirofiban has been shown to decrease in-hospital and possibly 30-day events after high-risk angioplasty. "( Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Boccuzzi, SJ; Burnette, J; Cohen, DJ; Cook, JR; Culler, S; Kosinski, AS; Weintraub, WS, 1999
)
1.95

Actions

Tirofiban did not increase the percentage of patients with initial patency of IRA (60.3% vs 64.0%, P=0.63) The tirofiba group had a lower frequency of total major cardiac events (26% vs 54%, P = 0.01)

ExcerptReferenceRelevance
"Tirofiban did not increase the risk of ICH (P = 0."( Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.
Liu, H; Liu, J; Yang, Y, 2022
)
1.69
"Tirofiban did not increase the percentage of patients with initial patency of IRA (60.3% vs 64.0%, P=0.63). "( [The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP, 2016
)
2.18
"Tirofiban did not increase initial patency in STEMI patients without early reperfusion therapy. "( [The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP, 2016
)
2.18
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding."( Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010
)
1.28
"The tirofiban group had a lower frequency of total major cardiac events (26% vs 54%, P = 0.01), acute MI (2.4% vs 19%, P = 0.03), and recurrent angina (26% vs 50%, P = 0.04)."( Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Cakmak, M; Cam, N; Okmen, E; Tartan, Z, 2003
)
0.8

Treatment

Tirofiban treatment was not associated with a lower level of disability and increased the incidence of sICH after endovascular therapy in cardioembolic stroke patients. Treatment also significantly decreased the rate of poor myocardial perfusion after PCI (19.7% vs 34.7%, P = 0.04)

ExcerptReferenceRelevance
"Tirofiban treatment did not correlate with a favorable shift towards a lower 90-day mRS score (adjusted common odds ratio [OR], 0.91; 95% CI 0.64-1.3; p = 0.617)."( Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial.
Gao, L; Guo, Z; Jiang, J; Li, F; Long, T; Luo, Y; Lv, Z; Meng, R; Qiu, Z; Rong, B; Tian, J; Xie, Y; Yang, Y; Yuan, Z; Zeng, H; Zhang, S; Zhao, J; Zi, W, 2023
)
1.98
"Tirofiban treatment was not associated with a lower level of disability and increased the incidence of sICH after endovascular therapy in cardioembolic stroke patients."( Association of tirofiban treatment with outcomes following endovascular therapy in cardioembolic stroke: insights from the RESCUE BT randomized trial.
Gao, L; Guo, Z; Jiang, J; Li, F; Long, T; Luo, Y; Lv, Z; Meng, R; Qiu, Z; Rong, B; Tian, J; Xie, Y; Yang, Y; Yuan, Z; Zeng, H; Zhang, S; Zhao, J; Zi, W, 2023
)
2.71
"IA tirofiban treatment did not increase the risk of mortality at 90 days of the index stroke (OR, 0.66; 95% CI, 0.36-1.31; P = .15)."( Safety of Intra-Arterial Tirofiban Administration in Ischemic Stroke Patients after Unsuccessful Mechanical Thrombectomy.
Bai, Y; Fan, X; Hao, Y; Li, S; Li, Z; Liu, X; Sun, B; Tian, X; Wang, H; Xu, G; Yang, D; Zhang, M; Zhang, S; Zhang, X; Zi, W, 2019
)
1.33
"Tirofiban treatment was also an independent predictor for poor outcome (odds ratio, 6.60; 95% confidence interval, 1.06-41.52; P=0.04) in addition to National Institute of Health Stroke Scale (odds ratio, 1.08; 95% confidence interval, 1.00-1.17; P=0.05)."( Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome.
Bendszus, M; Hacke, W; Hametner, C; Kellert, L; Ringleb, P; Rohde, S; Stampfl, S, 2013
)
1.4
"Tirofiban treatment also significantly decreased the rate of poor myocardial perfusion after PCI (19.7% vs 34.7%, P = 0.04)."( [The effects of tirofiban on acute non-ST segment elevation myocardial infarction patients not receiving early reperfusion intervention].
Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
1.47
"Tirofiban treatment does not increase the bleeding complications in NSTEMI patients without early PCI. "( [The effects of tirofiban on acute non-ST segment elevation myocardial infarction patients not receiving early reperfusion intervention].
Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
2.19
"Tirofiban early treatment is not better than the tirofiban bailout treatment during or after PCI in STEMI patients undergoing elective PCI. "( [Short- or long-outcome of early tirofiban in ST-segment elevated acute myocardial infarction undergoing elective percutaneous coronary intervention].
Gao, C; Hu, D; Li, M; Liu, H; Wang, X; Yang, H; Zhang, Y; Zhu, Z, 2014
)
2.13
"Tirofiban treatment was not associated with an increase in major bleeding even though there was a trend toward an increase in minor bleeding cases and did not influence the occurrence of refractory angina pectoris."( The effect of tirofiban on ST segment resolution in patients with non-ST elevated myocardial infarction.
Bayturan, O; Bilge, AR; Eser, E; Seküri, C; Tezcan, UK; Tikiz, H; Utük, O, 2004
)
1.41
"The tirofiban-treated group preserved the platelet count and tended to exert these beneficial effects by inhibiting pathologic platelet aggregation induced by TXA2, collagen, and ADP as well as degranulation."( Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation.
Chen, JC; Ishimaru, S; Powell, LL; Serna, DL; Wang, D; Wilson, SE; Yomo, T, 2000
)
0.79
"Treatment with tirofiban or eptifibatide had no effects on the favorable outcome (RR = 1.09, 95% CI 0.89-1.35, P = 0.411), functional outcome (RR = 1.12, 95% CI 0.98-1.28, P = 0.010), and last available NIHSS (WMD = - 2.32, 95% CI - 5.14 to 0.50, P = 0.106), but might increase mortality (RR = 0.84, 95% CI 0.71-0.99, P = 0.121)."( Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.
Liu, H; Liu, J; Yang, Y, 2022
)
1.31
"Treatment with tirofiban in patients with AIS with mechanical thrombectomy is effective in improving functional prognosis, arterial recanalization rates, and reducing 3-month mortality and re-occlusion rates, particularly in patients with large atherosclerotic stroke, without increasing the rate of symptomatic intracranial hemorrhage. "( Meta-analysis of the efficacy and safety of tirofiban in patients with acute ischaemic stroke undergoing mechanical thrombectomy.
Li, G; Liu, C; Liu, M; Wang, J; Yang, X, 2023
)
1.52
"Treatment with tirofiban did not influence recanalization rates."( Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome.
Bendszus, M; Hacke, W; Hametner, C; Kellert, L; Ringleb, P; Rohde, S; Stampfl, S, 2013
)
1.02
"Rats treated with tirofiban experienced a more pronounced decrease in their arterial pressure after acute SNP treatment than vehicle-treated rats."( Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.
Chamorro, A; Díez-Marqués, ML; Griera, M; Rodríguez-Puyol, D; Rodríguez-Puyol, M; Ruiz-Torres, MP, 2009
)
2.12
"Treatment with tirofiban was well tolerated in patients with progressive stroke. "( Treatment of progressive stroke with tirofiban--experience in 35 patients.
Glahn, J; Philipps, J; Rother, J; Schwarze, M; Thomalla, G, 2009
)
0.98
"Pretreatment with tirofiban proved safe and resulted in a significantly lower corrected Thrombolysis in Myocardial Infarction frame counts (21 vs 34, P = .008) indicating improved myocardial blood flow."( Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.
Gehl, HB; Giannitsis, E; Katus, HA; Kulke, C; Lehrke, S; Lima, JA; Merten, C; Richardt, G; Schuster, L; Steen, H; Wiegand, UK, 2005
)
0.86
"Pretreatment with tirofiban appears safe and improves myocardial flow after primary PCI with stenting. "( Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction.
Gehl, HB; Giannitsis, E; Katus, HA; Kulke, C; Lehrke, S; Lima, JA; Merten, C; Richardt, G; Schuster, L; Steen, H; Wiegand, UK, 2005
)
0.87

Toxicity

Tirofiban bolus over 3min followed by maintenance infusion appears to be a safe and efficient prophylactic protocol for the endovascular treatment of ruptured intracranial aneurysms.

ExcerptReferenceRelevance
" The primary endpoints were the proportion of patients with major bleeding and the rate of site access complications; the 30-day incidence of major adverse cardiac events (MACE) was also assessed."( Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Baglini, R; Capuano, C; Danzi, GB; Sesana, M, 2004
)
0.61
" It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors."( Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004
)
0.53
"50 mg/h) is a safe and feasible treatment for continuous pharmacological thrombolysis in ALI, potentially offering decreased infusion times and bleeding complications, as well as improved outcomes."( Continuous tenecteplase infusion combined with peri/postprocedural platelet glycoprotein IIb/IIIa inhibition in peripheral arterial thrombolysis: initial safety and feasibility experience.
Allie, AA; Allie, DE; Allie, SD; Chaisson, GA; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; Mitran, EV; Stagg, SJ; Vitrella, DA; Walker, CM; Wyatt, CH, 2004
)
0.32
"The results suggest that tirofiban is a safe and tolerable therapy for Korean patients with ACS."( Safety of tirofiban therapy in korean patients with acute coronary syndrome.
Chun, KJ; Hong, TJ; Jeong, JH; Kim, JH; Park, YH; Shin, YW, 2005
)
1.03
"The combination of DTI with bivalirudin and GP IIb-IIIa inhibition with tirofiban is a safe and feasible alternative anticoagulation and antiplatelet strategy in PPI, and may offer improved clinical and hemostasis outcomes in treating CLI."( A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome.
Allie, AA; Allie, DE; Allie, SE; Barker, EA; Chaisson, G; Fail, PS; Hebert, CJ; Keller, VA; Khan, MA; Khan, MH; Lirtzman, MD; McElderry, MW; Mitran, EV; Stagg, SJ; Vivekananthan, K; Walker, CM; Wyatt, CH, 2005
)
0.77
" Left ventricular ejection fraction (LVEF) and major adverse cardiac events (MACE, including death, re-infarction and target vessel revascularization) at 30 and 180 days after discharge were also compared."( [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
Shen, J; Zhang, Q; Zhang, RY, 2007
)
0.56
"Adjunctive therapy with tirofiban for patients with acute STEMI who undergo primary PCI is safe and can significantly improve re-perfusion in the infarct area and clinical outcomes at 30 as well as 180 days after procedure."( [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
Shen, J; Zhang, Q; Zhang, RY, 2007
)
0.87
"Firebird DES combining Tirofiban and Cypher DES combining Tirofiban are both safe and effective in treating ACS."( [Safety and efficacy of firebird drug-eluting stent combination tirofiban in patients with acute coronary syndrome].
Chen, YD; Li, WM; Liu, PD; Song, LY; Zhao, YJ; Zhou, LJ, 2008
)
0.9
"The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective."( Efficacy and safety of tirofiban in high-risk patients with non-ST-segment elevation acute coronary syndromes.
Jia, D; Li, Y; Nie, X; Yan, Z; Zhao, Y; Zhou, Y; Zhou, Z, 2009
)
0.98
"Tirofiban is safe and effective in patients with ACS."( Safety evaluation of tirofiban.
Tebaldi, M; Valgimigli, M, 2010
)
2.12
"We conclude that tirofiban might be safe in acute moderate ischemic stroke even when administered within a large time window after symptom onset and might save lives in the late outcome."( Safety of Tirofiban in acute Ischemic Stroke: the SaTIS trial.
Fiebach, JB; Hamann, G; Hennerici, MG; Junghans, U; Röther, J; Schneider, D; Seitz, RJ; Siebler, M; Villringer, A; von Reutern, GM; Witte, OW, 2011
)
1.11
" A maintenance infusion without an initial bolus, however, has an exceedingly low risk of hemorrhage and appears to be very safe and effective, even in the setting of SAH."( Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms.
Chalouhi, N; Hasan, D; Jabbour, P; Kung, D, 2012
)
0.69
" The primary end point was time to sheath removal and ambulation where as peri-procedure myocardial damage, access site bleeding and major adverse cardiac events (MACE) rates were secondary end points."( Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
Admane, P; Deshpande, NV; Mardikar, HM; Mukherjee, D; Pratiti, R,
)
0.13
"The combination of bivalirudin + tirofiban was safe and effective as compared to UFH + tirofiban in high risk patients undergoing elective PCI."( Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
Admane, P; Deshpande, NV; Mardikar, HM; Mukherjee, D; Pratiti, R,
)
0.41
" Bleeding, thrombosis and main adverse cardiovascular events (MACE) were compared between the two groups during hospitalization, at week 2 and week 4 after discharge."( [The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention].
Chen, Y; Gao, CY; Li, MW; Rao, LX; Zhao, XM; Zhu, ZY, 2013
)
0.63
" Major adverse cardiovascular events, comprising all-cause death, nonfatal infarction, nonfatal stroke, and ischaemia-driven target vessel revascularization, was the primary efficacy end point."( Efficacy and safety of tirofiban-supported primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel: results of propensity analysis using the Clinical Center of Serbia STEMI Register.
Asanin, M; Brdar, N; Djuricic, N; Krljanac, G; Lasica, R; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L, 2014
)
0.71
" In-hospital and 6-month major adverse cardiac events were recorded."( The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention.
Acikel, M; Aksakal, E; Bakirci, EM; Karal, H; Kaya, A; Kurt, M; Sevimli, S; Tanboga, IH; Topcu, S, 2015
)
0.67
"Our study revealed that 12-hour tirofiban administration versus 24-hour tirofiban administration in STEMI who underwent primary PCI was similar with respect to in-hospital efficacy and safety and major adverse cardiac events during 6-month follow-up."( The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention.
Acikel, M; Aksakal, E; Bakirci, EM; Karal, H; Kaya, A; Kurt, M; Sevimli, S; Tanboga, IH; Topcu, S, 2015
)
0.95
" Comparison of coronary blood flow, ST-segment resolution (STR), duration of hospital stay, 30-day major adverse cardiac events (MACE) and complications such as hemorrhage was conducted."( Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
Dong, PS; Han, YH; Lai, LH; Wang, HL; Xing, SY; Zhao, JF; Zhu, JH, 2014
)
0.68
"It was simple, safe and effective to perform intracoronary tirofiban administration in patients with serious thrombus burden and STEMI when undergoing emergency PCI."( Safety and efficacy of intracoronary tirofiban administration in patients with serious thrombus burden and ST-elevation myocardial infarction undergoing percutaneous coronary intervention.
Dong, PS; Han, YH; Lai, LH; Wang, HL; Xing, SY; Zhao, JF; Zhu, JH, 2014
)
0.92
" We evaluated the effects of tirofiban on thrombolysis in myocardial infarction (TIMI) grade 3 flow after PCI, TIMI myocardial perfusion grade 3 (TMP grade 3), left ventricular ejection fraction (LVEF), major adverse cardiovascular events (MACE), target vessel revascularization (TVR), death, reinfarction and adverse drug effects (specifically bleeding events)."( Efficacy and Safety of Intracoronary versus Intravenous Administration of Tirofiban during Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X, 2015
)
0.94
" Tirofiban may offer a safe and effective alternative as an antiplatelet premedication during stent-assisted coiling of acutely ruptured intracranial aneurysms."( Safety and Efficacy of Intravenous Tirofiban as Antiplatelet Premedication for Stent-Assisted Coiling in Acutely Ruptured Intracranial Aneurysms.
Cha, JK; Choi, JH; Huh, JT; Kang, M; Kim, S, 2016
)
1.62
"Tirofiban bolus over 3 min followed by maintenance infusion appears to be a safe and efficient prophylactic protocol for the endovascular treatment of ruptured intracranial aneurysms and may be an alternative to intraoperative oral antiplatelet therapy, especially in the case of stent-assisted embolization."( Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms.
Bai, WX; He, YK; Li, TX; Liang, XD; Wang, YY; Wang, ZL; Zhou, GY, 2016
)
2.14
"Being female is an independent predictor of adverse events during percutaneous coronary interventions (PCI)."( The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L, 2016
)
0.43
" The primary efficiency endpoint was 30-day net adverse clinical events (NACEs)."( The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Han, Y; Li, Y; Liang, Z; Liu, H; Ma, L; Stone, GW; Wang, D; Wang, J; Wang, S; Yang, L, 2016
)
0.43
" No significant differences were observed in major adverse cardiovascular events (MACE) (3."( [The effect and safety of tirofiban on acute ST segment elevation myocardial infarction patients receiving no early reperfusion therapy].
Li, WM; Liu, Y; Ni, ZH; Wang, HS; Wang, LF; Xia, K; Xu, L; Yang, XC; Zhang, DP, 2016
)
0.73
" After the follow-up, major adverse cardiac events were regarded as study endpoints in evaluating the safety of the combined therapy."( Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI).
Cao, Z; Gao, L; Zhang, H, 2016
)
0.66
"Intravenous tirofiban immediately after alteplase seems to be safe and potentially more effective when compared with alteplase alone for selected stroke patients."( Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
Chen, J; Feng, W; Huang, S; Li, W; Li, X; Liang, C; Lin, L; Liu, C; Wang, Y; Wu, Y; Zhang, M, 2016
)
1.08
" The primary outcome was 30-day net adverse clinical event (NACE), defined as a composite of major cardiac and cerebral events or any bleeding."( Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Bao, D; Chen, Y; Cong, H; Ding, S; Han, Y; Jia, S; Jing, Q; Li, J; Li, L; Li, Y; Liang, Z; Liu, B; Liu, H; Wang, H; Zhao, X, 2017
)
0.46
" Efficacy was evaluated in terms of major adverse cardiovascular event (MACE) parameters."( Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.
Ge, Z; Jiang, S; Kuang, J; Li, L; Ma, X; Zhang, D, 2017
)
0.71
" In this study, we aimed to investigate whether intravenous antiplatelet agent tirofiban was safe and potentially effective in AIS patients who had no visible arterial occlusion and was outside of treatment window for Alteplase."( Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies.
Feng, W; Huang, SH; Li, W; Li, XS; Liang, CR; Lin, L; Liu, CC; Wang, H; Wang, YJ; Wu, Y; Xu, ZQ; Zhang, LL; Zhang, M, 2017
)
0.94
"Intravenous tirofiban appears to be safe and potentially effective for the ischemic stroke patients with no artery occlusion on neurovascular imaging studies and being out of the window for thrombolytic therapy."( Safety and preliminary efficacy of intravenous tirofiban in acute ischemic stroke patient without arterial occlusion on neurovascular imaging studies.
Feng, W; Huang, SH; Li, W; Li, XS; Liang, CR; Lin, L; Liu, CC; Wang, H; Wang, YJ; Wu, Y; Xu, ZQ; Zhang, LL; Zhang, M, 2017
)
1.09
"Tirofiban appears to be safe for patients with acute cerebral infarct receiving endovascular therapy."( [Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy].
Chen, Z; Feng, X; Lou, M; Zhong, G, 2017
)
2.29
"Intra-arterial tirofiban may be safe in mechanical thrombectomy of acute ischemic stroke to facilitate the reperfusion of distal vessel, but has no beneficial effect on prognosis."( Safety and Efficiency of Low Dose Intra-arterial Tirofiban in Mechanical Thrombectomy During Acute Ischemic Stroke.
Fang, M; Jin, A; Lin, Y; Liu, X; Yu, T; Zhang, P; Zhou, X, 2018
)
1.09
" This is the first study investigating whether a planned use of GPIs during implantation of the Absorb BVS represents a safe and effective strategy in reducing ScT."( Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold.
Grove, MM; Jessup, DB; Kirby, A; Marks, S, 2018
)
0.48
" Tirofiban has been shown to improve ST-resolution, to decrease infarct size (IS) and to reduce incidence of major adverse cardiac and cerebrovascular events (MACCE)."( Safety and efficacy of Tirofiban in STEMI-patients.
Dannenberg, L; Helten, C; Hohlfeld, T; Kelm, M; Levkau, B; Mourikis, P; Naguib, D; Pöhl, M; Polzin, A; Schulze, V; Wolff, G; Zako, S; Zeus, T, 2019
)
1.73
"Low-dose IA tirofiban administration may be relatively safe in patients with ischemic stroke after unsuccessful recanalization."( Safety of Intra-Arterial Tirofiban Administration in Ischemic Stroke Patients after Unsuccessful Mechanical Thrombectomy.
Bai, Y; Fan, X; Hao, Y; Li, S; Li, Z; Liu, X; Sun, B; Tian, X; Wang, H; Xu, G; Yang, D; Zhang, M; Zhang, S; Zhang, X; Zi, W, 2019
)
1.2
" Patients with successful PCI and no cardiogenic shock who were anticoagulated with either of the above regimens were followed for 30-day major bleeding and major adverse cardiovascular events (death, nonfatal myocardial infarction, and urgent target vessel revascularization) at 30 days, 1 year, and long term."( Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry).
Anderson, JL; Bair, TL; Hackett, IS; Knowlton, KU; Lappé, DL; Le, VT; May, HT; Muhlestein, JB; Whisenant, B, 2019
)
0.74
"Early antiplatelet therapy may be safe in acute ischemic stroke patients, further studies are needed to confirm the efficacy."( Safety and efficacy of early antiplatelet therapy in acute ischemic stroke patients receiving endovascular treatment: A systematic review and meta-analysis.
Guo, Y; Lin, Y; Pan, X; Tang, Q; Tang, Y; Wang, X; Yang, J; Zou, J, 2019
)
0.51
"Our study suggests that long-term use of intravenous tirofiban monotherapy in aSAH subjects for endovascular SAC or FDD is safe in the perioperative setting."( The Safety and Efficacy of Continuous Tirofiban as a Monoantiplatelet Therapy in the Management of Ruptured Aneurysms Treated Using Stent-Assisted Coiling or Flow Diversion and Requiring Ventricular Drainage.
Al Kasab, S; Alvarez, C; Dandapat, S; Hasan, D; Hudson, J; Jabbour, P; Kung, DK; Limaye, K; Nakagawa, D; Ortega-Gutierrez, S; Samaniego, EA; Zanaty, M, 2019
)
1.03
"The use of IA tirofiban during MT seems to be safe and potentially more effective than only MT without IA tirofiban, even in patients who used IV t-PA before MT."( Safety and Efficacy of Intra-arterial Tirofiban Injection During Mechanical Thrombectomy for Large Artery Occlusion.
Lee, DH; Sung, JH; Yi, HJ, 2019
)
1.15
"To conclude, tirofiban appears to be safe when used following IV thrombolysis or as monotherapy in AIS patients."( Safety and efficacy of tirofiban in acute ischemic stroke patients not receiving endovascular treatment: a systematic review and meta-analysis.
Gao, Y; Ma, QL; Zhou, J, 2020
)
1.24
"Tirofiban is safe in AIS patients with ET and can significantly reduce mortality; preoperative tirofiban may be effective, but further studies are needed to confirm the efficacy."( Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Receiving Endovascular Treatment: A Meta-Analysis.
Fu, Z; Gao, L; Liu, X; Wang, Z; Xu, C, 2020
)
2.31
"Whether tirofiban is safe and effective for acute ischemic stroke (AIS) patients undergoing mechanical thrombectomy (MT) with preceding intravenous thrombolysis (IVT) remains unclear."( Safety and Efficacy of Tirofiban During Mechanical Thrombectomy for Stroke Patients with Preceding Intravenous Thrombolysis.
Gao, F; Huo, X; Li, X; Ma, N; Miao, Z; Mo, D; Wang, A; Wang, Y; Yang, M, 2020
)
1.3
" Tirofiban combined with EVT appears to be safe and potentially effective in treating AIS."( Safety and efficacy of tirofiban combined with endovascular therapy compared with endovascular therapy alone in acute ischemic stroke: a meta-analysis.
Guo, ZN; Qin, H; Sun, Y; Wang, M; Wang, Y; Yan, X; Yang, Y; Zhang, P; Zhu, H, 2021
)
1.84
" However, there were no significant differences in the adverse drug reactions between the two groups."( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke.
Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021
)
2.06
" Intravenous (IV) tirofiban alone or combined with DAPT was shown to be safe and effectively improved clinical outcome in progressive ischemic stroke patients."( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021
)
1.23
"Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found."( Association between tirofiban monotherapy and efficacy and safety in acute ischemic stroke.
Chen, C; Hu, W; Liu, D; Liu, J; Liu, T; Luo, W; Song, J; Tao, C; Yuan, X; Zhang, C; Zhu, Y, 2021
)
1.25
" The tirofiban efficacy was evaluated in terms of major adverse cardiovascular event (MACE) parameters and lab endpoints, including platelet count and function."( Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI.
Chen, LL; Guo, YZ; Li, SM; Zhao, ZW, 2021
)
1.42
" Tirofiban appears to be a safe and alternative during the stent-assisted coiling of ruptured intracranial aneurysms."( Safety and efficacy of intravenous tirofiban for stent-assisted coiling in acutely ruptured intracranial aneurysms: A single center experience.
Chen, X; Feng, Y; Jia, C; Ma, Y; Zhang, T; Zhao, W, 2022
)
1.91
"Intravenous administration of a low dose of tirofiban may represent a safe and effective alternative to DAPT during stent-assisted coiling of RIAs."( The safety and efficacy of a low dose of tirofiban for early complications during and after stent-assisted coiling of ruptured intracranial aneurysms: A propensity matching study.
Jia, Z; Liu, S; Lu, G; Shen, G; Shi, H; Zhao, L, 2022
)
1.25
" The primary outcome was the success rate of no major adverse cardiovascular events (MACE)."( Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z, 2022
)
0.72
"The results of this study showed that the use of intravenous platelet glycoprotein IIb/IIIa inhibitors as a bridging strategy might be safe and effective for patients undergoing coronary stent implantation that require surgery soon after."( Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: a meta-analysis.
Chang, J; Han, B; Luo, Y; Ma, K; Mao, M; Wu, F; Xiang, R; Zuo, Z, 2022
)
0.72
" In-hospital major adverse coronary events (MACE, defined as death, reinfarction, stent thrombosis, and target vessel revascularization), final TIMI flow, myocardial blush grade, and ST-segment resolution were also evaluated."( Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
Esposito, G; Ettori, F; Ferlini, M; Lettieri, C; Marchese, A; Musumeci, G; Passamonti, E; Pierini, S; Rigattieri, S; Romano, M; Tarantini, G; Testa, L; Tiberti, G, 2022
)
0.96
" The observation group had a lower incidence of adverse reactions."( Efficacy and safety assessment of urokinase plus tirofiban in acute cerebral infarction patients without clear criminal vessels.
Gao, Y; Tian, W; Yang, H; Yang, Z; Zhang, T, 2022
)
0.98
"A low dose of tirofiban, regardless of their administration routes, was safe for AIS patients who achieved successful recanalization with EVT, whereas only IA + IV tirofiban improved clinical outcomes."( Safety and efficacy of different tirofiban administration routes on acute ischemic stroke patients with successful recanalization: A propensity score matching analysis.
Chen, J; Duan, J; Guo, W; Ji, X; Li, C; Li, S; Ma, J; Ma, L; Ma, Q; Ren, C; Song, H; Wu, C; Wu, L; Xu, J; Zhao, W, 2022
)
1.36
"Through simulation verification, it is concluded that tirofiban combined with statins is safe and effective in the perioperative application of intracranial aneurysms."( Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.
Hao, M; Liu, R; Luo, Y; Yan, F, 2022
)
1.28
" Adverse reactions during the intervention were recorded for safety analysis."( The efficacy and safety of intravenous tirofiban in the treatment of acute ischemic stroke patients with early neurological deterioration.
Du, Y; Duan, Z; Li, S; Li, Y; Lian, Y; Liu, R; Ma, C; Wang, H, 2022
)
0.99
" Tirofiban is effective and safe in patients with AIS."( Meta-analysis of the efficacy and safety of tirofiban in patients with acute ischaemic stroke undergoing mechanical thrombectomy.
Li, G; Liu, C; Liu, M; Wang, J; Yang, X, 2023
)
2.08
"FD insertion combined with coil embolization is a potentially safe and effective therapeutic strategy for ruptured aneurysms when accompanied with perioperative evidence-based antithrombotic therapy."( Efficacy and safety of flow diverter combined with coil embolization and evidence-based antithrombotic regimen in the treatment of ruptured aneurysms.
Chen, Z; Gong, W; Guan, S; Li, D; Li, Y; Liu, C; Xu, H; You, W, 2023
)
0.91
" Tirofiban is safe and effective in both anterior circulation stroke and posterior circulation stroke patients undergoing EVT."( Systematic review and meta-analysis of the efficacy and safety of adjunctive use of tirofiban in patients treated with endovascular therapy for acute ischemic stroke at different embolic sites.
Li, G; Liu, C; Liu, M; Wang, J; Yang, X, 2023
)
2.04

Pharmacokinetics

The objective of the present study was to identify an appropriate dosage of tirofiban that would produce a plasma concentration-time profile in patients with severe renal impairment. The results show that administration of reviparin together with abciximab did not adversely affect the pharmacodynamic profile of these GPIIb/IIIa-antagonists.

ExcerptReferenceRelevance
"The objective of our study was to define the interaction between either unfractionated heparin (UFH) or a low molecular weight heparin, reviparin (REV), and the pharmacodynamic profile of the GPIIb/IIIa-antagonists abciximab (ABC) or tirofiban (T)."( Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Breddin, HK; Esslinger, HU; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D, 2001
)
0.73
" The pharmacodynamic effects measured were bleeding time (BT), fibrinogen-binding at the GPIIb/IIIa-receptor (FIB), expression of the platelet secretion marker CD62, and ADP (20 microM)- and collagen (5 microg ml(-1))-induced platelet aggregation."( Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Breddin, HK; Esslinger, HU; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D, 2001
)
0.54
" The results show that administration of reviparin together with abciximab or tirofiban did not adversely affect the pharmacodynamic profile of these GPIIb/IIIa-antagonists."( Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Breddin, HK; Esslinger, HU; Graff, J; Harder, S; Kirchmaier, CM; Klinkhardt, U; Westrup, D, 2001
)
0.77
" Dose selection for the initial trials using the three parenteral antagonists was based on in vitro and ex vivo pharmacodynamic assays conducted under different blood collection and platelet function assay conditions."( The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Jacoski, MV; Jennings, LK; White, MM, 2002
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The objective of the present study was to use pharmacokinetic modeling to identify an appropriate dosage of tirofiban that would produce a plasma concentration-time profile in patients with severe renal impairment (creatinine clearance<30 ml/min) as similar as possible to that of the HDB regimen in patients with normal renal function."( Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
Janzen, MC; Lakings, DB; Schneider, DJ, 2012
)
0.83

Compound-Compound Interactions

Enoxaparin, relative to unfractionated heparin, resulted in less variability and a trend toward greater inhibition of platelet aggregation using 5 microM adenosine phosphate agonist.

ExcerptReferenceRelevance
" When combined with tirofiban, enoxaparin, relative to unfractionated heparin, resulted in less variability and a trend toward greater inhibition of platelet aggregation using 5 microM adenosine phosphate agonist."( Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen, M, 2000
)
0.83
" In the present study the efficacy of tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, combined with heparin or low-molecular-weight heparin (dalteparin), was evaluated for the management of ACS."( Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH, 2005
)
0.6
"Tirofiban combined with dalteparin was associated with relatively more bleeding complications in the short term, but was effective in reducing the incidence of MACE during long-term clinical follow-up in patients with ACS."( Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH, 2005
)
1.77
" Since the pathophysiology of acute ischemic cardiac diseases involves haemostatic impairment and the therapeutic regimen includes antithrombotic drugs, we investigated the effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with platelet aggregation inhibitors (aspirin, eptifibatide and tirofiban), unfractionated heparin, low molecular weight heparin (enoxaparin) or the recombinant fibrinolytic drug (alteplase), on various haemostatic parameters in vitro."( In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Kecskés, M; Losonczy, H; Nagy, A; Pótó, L; Szabó, C; Tóth, O, 2006
)
0.71
"A patient admitted for coronary angioplasty received a loading dose of Clopidogrel 600 mg, in combination with an infusion of Tirofiban and one prophylactic dose of Enoxaparin."( Cerebellar hematoma complicating 600 mg loading dose of clopidogrel in combination with tirofiban.
Aoun, N; Azar, R; Kadri, Z; Moussa, R; Sarkis, A, 2008
)
0.77
"This prospective study was conducted to investigate the clinical outcomes and safety of primary percutaneous coronary intervention (PCI) combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction (STEMI)."( [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
Shen, J; Zhang, Q; Zhang, RY, 2007
)
0.76
"One hundred and sixty consecutive patients with acute STEMI were randomly allocated to either primary PCI combined with tirofiban therapy (Tirofiban group, n = 80) or primary PCI treatment alone (Control group, n = 80)."( [Clinical outcomes and safety of primary percutaneous coronary intervention combined with tirofiban therapy in patients with acute ST-segment elevation myocardial infarction].
Shen, J; Zhang, Q; Zhang, RY, 2007
)
0.77
" This study aimed to determine the clinical outcomes of tirofiban combined with the low molecular weight heparin (LMWH), dalteparin, in primary PCI patients with acute STEMI."( Comparison of tirofiban combined with dalteparin or unfractionated heparin in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction patients.
Ge, YG; Li, WM; Ni, ZH; Wang, HS; Wang, LF; Xu, L; Yang, XC; Zhang, DP, 2011
)
0.98
"Thrombus aspiration combined with intracoronary tirofiban during recovery from acute MI was effective and relatively well tolerated."( Clinical evaluation of thrombus aspiration combined with tirofiban in patients with acute myocardial infarction with elective percutaneous coronary intervention.
Dong, P; Li, Z; Liu, X; Wang, H; Wang, S; Xing, S; Yang, X; Zhai, Q; Zhang, H, 2013
)
0.89
"To explore the efficacy and safety of fondaparinux combined with tirofiban in patients with high risk unstable angina (UA) undergoing complex percutaneous coronary intervention (PCI) ."( [The clinical efficacy and safety of fondaparinux combined with tirofiban hydrochloride in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention].
Chen, Y; Gao, CY; Li, MW; Rao, LX; Zhao, XM; Zhu, ZY, 2013
)
0.87
"To explore the impact of intracoronary bolus administration of tirofiban combined with nitroprusside through thrombus aspiration catheter or thrombus aspiration alone on myocardial reperfusion and major adverse cardiovascular events rate in acute anterior myocardial infarction patients with heavy thrombosis burden."( [Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden].
Du, J; Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
0.95
"5) years old] were randomly assigned to thrombus aspiration group (Group A, n = 30), thrombus aspiration and intracoronary tirofiban bolus (25 µg/kg prior to the first balloon inflation,Group B, n = 30), thrombus aspiration and intracoronary tirofiban combined with nitroprusside bolus (200 µg prior to the first balloon inflation, Group C, n = 30) with random number table."( [Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden].
Du, J; Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
0.91
"Intracoronary bolus application of tirofiban combined with nitroprusside through thrombus aspiration catheter after thrombus aspiration is associated with an improvement of myocardial reperfusion without increasing bleeding complication and other adverse cardiovascular events rate compared with thrombus aspiration alone in patients with acute anterior myocardial infarction and heavy thrombosis burden undergoing primary PCI."( [Effect of intracoronary tirofiban combined with nitroprusside injection through thrombus aspiration catheter during primary percutaneous coronary intervention on acute anterior myocardial infarction patients with heavy thrombosis burden].
Du, J; Li, W; Liu, Y; Ni, Z; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
0.98
" CONCLUSIONS The use of thrombectomy combined with intracoronary administration of tirofiban is relatively effective and safe in STEMI patients undergoing PPCI."( Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI).
Cao, Z; Gao, L; Zhang, H, 2016
)
0.89
"To investigate the curative effect of tirofiban combined with recombinant tissue-plasminogen activator (rt-PA) selective intra-arterial thrombolysis on acute middle cerebral artery occlusion (MCAO)."( Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Xiong, W; Yu, YJ, 2018
)
2.19
"Early application of tirofiban combined with rt-PA in intra-arterial thrombolysis for ultra-early cerebral ischemia can improve the recanalization rate of cerebral artery."( Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Xiong, W; Yu, YJ, 2018
)
2.24
" This study evaluated the efficacy and safety of tirofiban in combination with EVT for AIS."( Safety and efficacy of tirofiban combined with endovascular treatment in acute ischaemic stroke.
Chan, PWL; Lin, Y; Pan, X; Yang, J; Zheng, D; Zheng, Y; Zhou, J; Zou, J, 2019
)
1.08
"This study explores the safety and effect of acute cerebral infarction treatment by microcatheter injection of tirofiban combined with a Solitaire AB stent and/or stent implantation."( Clinical efficacy of tirofiban combined with a Solitaire stent in treating acute ischemic stroke.
Cao, PW; Chen, GF; Fu, C; Fu, XM; Wang, L; Zhang, GQ; Zhang, QQ; Zhang, Y, 2019
)
1.04
" However, the safety and efficacy of treating AIS with tirofiban combined with EVT remain controversial."( Safety and efficacy of tirofiban combined with endovascular therapy compared with endovascular therapy alone in acute ischemic stroke: a meta-analysis.
Guo, ZN; Qin, H; Sun, Y; Wang, M; Wang, Y; Yan, X; Yang, Y; Zhang, P; Zhu, H, 2021
)
1.18
"This study aimed to explore the effect of sulfotanshinone sodium injection combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome (ACS)."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.08
" Patients treated with sulfotanshinone sodium injection combined with tirofiban (n = 99) were allocated to the research group (RG), and the remaining patients treated with tirofiban alone were allocated to the control group (n = 70; CG)."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.09
"Compared with tirofiban alone, sulfotanshinone sodium injection combined with tirofiban had superior efficacy and safety in the treatment of ACS."( Prospective study of the effect of sulfotanshinone sodium combined with tirofiban on vascular endothelial function and indicators of plaque stability in elderly patients with acute coronary syndrome.
He, X; Lin, S; Wang, C; Xue, H; Zhai, G, 2021
)
1.21
"Tirofiban can be used to treat patients with acute ischemic stroke (AIS), this study was to evaluate the efficacy and safety of tirofiban combined with heparin in the treatment of mild to moderate AIS."( Tirofiban combined with heparin's effect and safety in the treatment of mild to moderate acute ischemic stroke.
Chen, M; Dai, X; Deng, X; Fu, S; Gong, Q; He, W; Huang, L; Li, C; Luo, Q; Qiu, T; Wang, J; Wang, M; Xiao, H, 2021
)
3.51
"In this meta-analysis, we explored whether tirofiban could safely improve outcomes when combined with endovascular therapy in acute ischemic stroke with large vessel occlusion."( Sequential tirofiban infusions combined with endovascular treatment may improve outcomes in acute ischemic stroke - a meta-analysis.
Cao, W; Dong, Q; Feng, Y; Ling, Y; Mao, Y; Rong, X; Wang, Z; Zhao, H, 2021
)
1.27
"This study assessed the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy (DAPT) in progressive ischemic stroke."( Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021
)
1.15
"To investigate the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris (UA)."( Comparison of the effect of ticagrelor combined with tirofiban versus clopidogrel combined with tirofiban on inflammation response and prognosis of patients with unstable angina pectoris in long term follow-up.
Deng, L; Jia, HZ; Li, MC; Zhu, W, 2021
)
1.12
"To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function."( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Li, F; Peng, R, 2022
)
1.3
" On the basis of conventional treatment, patients were separated into a joint group (tirofiban combined with ticagrelor and aspirin) comprising 55 cases and a control group (conventional ticagrelor and aspirin dual treatment) involving 47 cases."( The Clinical Efficacy of Tirofiban Combined with Ticagrelor and Aspirin in Treating Acute Myocardial Infarction by Percutaneous Coronary Intervention and Its Effect on Patients' Cardiac Function.
Li, F; Peng, R, 2022
)
1.25
" We evaluated the safety and efficacy of balloon dilation in combination with tirofiban as the first-line salvage therapy when MT failed in these patients."( Balloon Angioplasty Combined with Tirofiban as a First-Line Rescue Treatment After Failed Mechanical Thrombectomy for Middle Cerebral Artery Occlusion with Underlying Atherosclerosis.
Hang, Y; Jia, ZY; Liu, S; Ni, H; Shi, HB; Wang, CD; Zhao, LB, 2022
)
1.23
"We retrospectively analyzed the records of 47 patients admitted between January 2018 and June 2021, with middle cerebral artery atherosclerotic occlusion, who underwent balloon angioplasty in combination with tirofiban as the first-line salvage therapy after the failure of MT."( Balloon Angioplasty Combined with Tirofiban as a First-Line Rescue Treatment After Failed Mechanical Thrombectomy for Middle Cerebral Artery Occlusion with Underlying Atherosclerosis.
Hang, Y; Jia, ZY; Liu, S; Ni, H; Shi, HB; Wang, CD; Zhao, LB, 2022
)
1.19
"Balloon angioplasty in combination with tirofiban is safe and effective for middle cerebral artery atherosclerotic occlusion after the failure of MT."( Balloon Angioplasty Combined with Tirofiban as a First-Line Rescue Treatment After Failed Mechanical Thrombectomy for Middle Cerebral Artery Occlusion with Underlying Atherosclerosis.
Hang, Y; Jia, ZY; Liu, S; Ni, H; Shi, HB; Wang, CD; Zhao, LB, 2022
)
1.27
"In order to verify the safety and effectiveness of tirofiban combined with statins in the perioperative period of intracranial aneurysms, this study adopts systematic review and meta-analysis, so as to comprehensively understand the situation of intracranial aneurysms in the perioperative period, and tirofiban combined with statins was finally determined as an effective treatment drug."( Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.
Hao, M; Liu, R; Luo, Y; Yan, F, 2022
)
1.28
" Through conventional drugs and tirofiban combined with statins used in this study, the intracranial levels, the probability of aneurysm rupture, and postoperative complications of the two groups were observed and recorded."( Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.
Hao, M; Liu, R; Luo, Y; Yan, F, 2022
)
1.32
"Through simulation verification, it is concluded that tirofiban combined with statins is safe and effective in the perioperative application of intracranial aneurysms."( Safety and Efficacy of Tirofiban Combined with Statins in the Perioperative Period of Intracranial Aneurysms: Systematic Review and Meta-Analysis.
Hao, M; Liu, R; Luo, Y; Yan, F, 2022
)
1.28
"FD insertion combined with coil embolization is a potentially safe and effective therapeutic strategy for ruptured aneurysms when accompanied with perioperative evidence-based antithrombotic therapy."( Efficacy and safety of flow diverter combined with coil embolization and evidence-based antithrombotic regimen in the treatment of ruptured aneurysms.
Chen, Z; Gong, W; Guan, S; Li, D; Li, Y; Liu, C; Xu, H; You, W, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" However, the clinical development of orally active RGD analogs has been hindered by the low oral bioavailability of many such RGD analogs."( A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics.
Borchardt, RT; Camenisch, G; Hugger, E; Sane, DC; Wang, B; Wang, W; Wheeler, GL; Zhang, H, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The current dosing of tirofiban may be inadequate to achieve appropriate platelet inhibition during PCI in patients admitted with acute coronary syndrome. However, the safety and efficacy of optimal dosage and the reasonable treatment is still unknown.

ExcerptRelevanceReference
" The method was specific and no immunoreactive material other than the parent drug was detectable in plasma and urine from dosed volunteers."( Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay.
Gilbert, JD; Hand, EL; Hichens, M; Olah, TV; Yuan, AS, 1994
)
0.29
"This study establishes a rational and generally well tolerated dosing regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients."( Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD, 1996
)
0.75
" Dosing strategies and treatment duration still need to be refined, especially for the competitive antagonists."( Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng, JE, 1996
)
0.29
" Future studies will be aimed at optimizing results and improving safety through more accurate assessment of optimal dosage and duration of infusion."( [Clinical use of glycoprotein IIb/IIIa inhibitors].
Gallopin, M; Gensini, GF; Simonetti, I,
)
0.13
" A reduced dose of the thrombin inhibitor with the standard dose of the antiplatelet drug was the dosing regimen used."( Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Bakhos, M; Fareed, J; Jeske, WP; Lewis, BE; Leya, F; Walenga, JM; Wallis, DE, 1999
)
0.3
" These can be minimized by changes in heparin dosing and careful management of vascular sheaths."( Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Adgey, AA; Mathew, TP, 1999
)
0.3
"125 microg/kg/min) or tirofiban, with either the PRISM-PLUS dosage (0."( Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.
Holmes, MB; Kabbani, SS; Schneider, DJ; Sobel, BE; Terrien, CM; Watkins, MW, 2001
)
0.83
", Whitehouse Station, New Jersey]) all sought to identify dosing regimens that would establish and maintain >80 % inhibition of ex vivo platelet aggregation throughout the duration of intravenous infusion."( Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos, G, 2001
)
0.31
" Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs."( Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
Vernon, SM, 2001
)
0.31
" The second issue is whether early use of an aggressively dosed statin is superior to a current trial-based "accepted care" regimen of a lower-dose statin started 3 to 6 months after an acute event."( The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Bilheimer, D; Blazing, MA; Braunwald, E; Califf, RM; De Lemos, JA; Dyke, CK, 2001
)
0.51
" A combination of tirofiban and lepirudin was used with dosing adjusted for renal insufficiency."( Adjunctive therapies in the cath lab. Use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia.
Caputo, RP; Esente, P; Giambartolomei, A; Reger, M; Simons, A; Wagner, S, 2001
)
0.64
" Recent comparative pharmacodynamics studies, which used newly defined and standardized assay conditions, indicate that the platelet aggregation inhibition achieved with these dosing regimens is variable."( The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors.
Jacoski, MV; Jennings, LK; White, MM, 2002
)
0.31
" In particular, these trials indicate: (i) the importance of selecting high-risk patients in whom substantial clinical benefit is evident, (ii) the incorporation of these agents into an early invasive strategy, thereby matching the timing of vascular injury with maximal platelet inhibition and (iii) optimal dosing to achieve the high levels of platelet inhibition that appear to be required for efficacy with these agents."( Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
Bhatt, DL; Chew, DP, 2002
)
0.31
" The current dosing of tirofiban may be inadequate to achieve appropriate platelet inhibition during PCI in patients admitted with acute coronary syndrome and receiving tirofiban immediately before the procedure in the cardiac catheterization laboratory."( Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Bobek, J; Farmer, J; Lakiss, N; Lakkis, N, 2002
)
0.93
" Further investigation is needed to ascertain the optimal dosing of tirofiban and heparin to achieve reductions in ischemic complications of intracoronary stenting with an acceptable incidence of bleeding complications."( A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.
Adgey, AA; Belardi, JA; Bunt, T; Herrmann, HC; Juergens, CP; Levy, RD; Macaya, C; Menten, J; Meyer, BJ; Soler-Soler, J; Tarnesby, G; White, HD, 2002
)
0.81
" Nevertheless, none of these fibans was able to effectively block shear-induced platelet adhesion at targeted clinical dosing regimens except for abciximab."( Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Barbera, FA; Dorsam, RT; Feuerstein, GZ; Friedman, SM; Gibbs, S; Lauver, A; Savion, N; Varon, D; Wang, H; Wang, X, 2002
)
0.31
" During medication with GP IIb/IIIa inhibitor, the patients received a reduced heparin dosage for 24 hours."( Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.
Forkmann, L; Hellner, G; Kirch, W; Koch, R; Müller, A; Schweizer, J,
)
0.45
" Tirofiban and abciximab appear effective and safe when used for ACS when recommended dosing and precautions are followed."( Differential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practice.
Beauchamp, GD; Brosnahan, K; Gowda, MS; Lakkireddy, DJ; Vacek, JL,
)
1.31
" Potential reasons for arterial reocclusion may be increased platelet activation, interaction of platelets with other cell types such as leukocytes and inadequate drug dosing due to lack of ideal platelet monitoring."( Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
Bekeredjian, R; Bertram, U; Bode, C; Kuecherer, HF; Moser, M; Nordt, TK; Peter, K; Ruef, J; Straub, A, 2002
)
0.55
" Study group 1 (10 healthy volunteers) received a DDAVP infusion to establish dose-response curves for the in vitro inhibition of platelet function by eptifibatide, abciximab, and tirofiban together with l-aspirin before and after DDAVP."( Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.
Blazicek, H; Domanovits, H; Galehr, E; Jilma, B; Jilma-Stohlawetz, P; Mayr, F; Reiter, RA, 2003
)
0.51
" However, the question of their usefulness in different clinical scenarios (stable or unstable coronary disease, without PCI) has not been fully answered on the basis of considerations of dosing and cost-effectiveness."( Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.
De Caterina, R; Zimarino, M, 2004
)
0.32
" Taking into account the differences in clinical efficacy of these 2 drugs in large trials investigating percutaneous coronary intervention, we hypothesized that the variable clinical effects might be related to variability in the magnitude and consistency of platelet aggregation inhibition achieved with dosing regimens of these glycoprotein IIb/IIIa inhibitors."( Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Cook, SL; Garza, L; Jacoski, MV; Jennings, LK; Matin, Z; McGrew, FA; Ramanathan, KB; Saucedo, JF; Wolford, DC, 2004
)
0.57
" Due to existing data indicating that standard dosing of tirofiban is insufficient for optimal platelet inhibition, we proposed a novel, experimental dosing."( Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Dobrzycki, S; Gajewska-Bachórzewska, H; Gugała, K; Kochman, W; Korecki, J; Kralisz, P; Mezyński, G; Musiał, W; Nowak, K; Poniatowski, B; Prokopczuk, P; Zuk, J, 2004
)
0.85
"In this study we assessed, with the use of Ultegra Rapid Platelet Function Assay (RFPA), the level of platelet inhibition with increased tirofiban dosing during primary PCI for ST elevation myocardial infarction (STEMI)."( Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Dobrzycki, S; Gajewska-Bachórzewska, H; Gugała, K; Kochman, W; Korecki, J; Kralisz, P; Mezyński, G; Musiał, W; Nowak, K; Poniatowski, B; Prokopczuk, P; Zuk, J, 2004
)
0.81
" Increased dosing of tirofiban resulted in an enhanced platelet inhibition."( Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Dobrzycki, S; Gajewska-Bachórzewska, H; Gugała, K; Kochman, W; Korecki, J; Kralisz, P; Mezyński, G; Musiał, W; Nowak, K; Poniatowski, B; Prokopczuk, P; Zuk, J, 2004
)
0.92
" We investigated if a novel regimen of dosage of tirofiban administered to patients with acute myocardial infarction with ST elevation (STEMI) before primary angioplasty is safe, feasible and whether such treatment improves coronary flow in infarct-related artery."( Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.
Bachorzewska-Gajewska, H; Chlopicki, S; Dobrzycki, S; Gugala, K; Kochman, W; Korecki, J; Kralisz, P; Mezynski, G; Musial, WJ; Niewada, M; Nowak, KS; Poniatowski, B; Prokopczuk, P, 2004
)
0.83
" Parameters evaluated as possible risk factors for bleeding included age, renal function, weight, heparin and glycoprotein IIb/IIIa inhibitor dosing and infusion duration, concomitant antiplatelet and/or anticoagulant medications or disease states, and baseline hemoglobin, hematocrit, or platelet counts."( Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Brouse, SD; Wiesehan, VG, 2004
)
0.32
" Specifically, there was no difference in the tirofiban dose-response curves with either platelet agonist for any of the three time points (before, and three and six hours after, clopidogrel administration)."( Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Berger, PB; DiBattiste, PM; Lennon, R; Lubbe, D; Orford, JL; Talreja, D, 2004
)
0.58
" The objective of this study was to conduct a detailed time-resolved analysis of the effects of the GPIIb/IIIa inhibitor tirofiban with concomitant clopidogrel in ACS patients undergoing percutaneous coronary intervention (PCI) to improve the dosing regimen of these two commonly used antiplatelet drugs."( Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Badar, J; Covic, L; Jacques, S; Kimmelstiel, C; Kuliopulos, A; Waxman, S; Weintraub, A, 2005
)
0.77
"This study shows that the currently utilized tirofiban dosage is suboptimal and suggests that patients may benefit from a higher dose regimen."( Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Badar, J; Covic, L; Jacques, S; Kimmelstiel, C; Kuliopulos, A; Waxman, S; Weintraub, A, 2005
)
0.82
"Optimal timing and dosage of glycoprotein IIb/IIIa inhibitors for ACS remain to be explored."( Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Cosmi, F; Ducci, K; Falsini, G; Liistro, F; Taddei, T; Tarducci, R, 2006
)
0.61
"Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events."( Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Angiolillo, D; Arora, U; Atar, D; Malinin, A; Pokov, A; Serebruany, V, 2007
)
0.63
" It was shown that standard dosing of tirofiban is insufficient for optimal platelet inhibition."( Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
Akbulut, T; Akgoz, H; Bilsel, T; Ciloglu, F; Dayi, SU; Ergelen, M; Sayar, N; Terzi, S; Yesilcimen, K, 2006
)
0.92
"Although angiographic and clinical benefits were not demonstrated, the results suggest that research into an effective and uniform dosing regimen of adjunctive tirofiban therapy for PCI is warranted."( Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
Chen, SM; Fang, CY; Fu, M; Guo, GB; Hsieh, YK; Wu, CJ; Yip, HK, 2006
)
0.73
" Data indicate that eptifibatide, at the current recommended dosing schedule, achieves the highest level of consistent platelet inhibition compared with current doses of abciximab and tirofiban."( Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Jennings, LK, 2005
)
0.52
" The contribution of dosing to the observed sex-related differences in bleeding is unknown."( Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB, 2006
)
0.33
"Women experience more bleeding than men whether or not they are treated with GP IIb/IIIa inhibitors; however, because of frequent excessive dosing in women, up to one fourth of this sex-related risk difference in bleeding is avoidable."( Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
Alexander, KP; Chen, AY; Gibler, WB; Hochman, JS; Newby, LK; Ohman, EM; Peterson, ED; Redberg, RF; Roe, MT; Schwartz, JB, 2006
)
0.33
" The object of this study was to confirm that high dose tirofibal is associated with over 90% platelet inhibition during the first hour and to analyse the effect of this new dosage on platelet activation."( [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
Alessi, MC; Barbou, F; Bonnet, JL; Cuisset, T; Frère, C; Hovasse, T; Quilici, J; Said, LN, 2006
)
0.59
" Subsequently, a high-bolus dose of tirofiban (25 microg/kg bolus) followed by standard infusion was tested and evidence suggest that in this dosing tirofiban may be as effective as abciximab and have a comparable safety profile."( Current strategies with high-dose tirofiban.
Mukherjee, D; Roffi, M, 2007
)
0.89
" In addition, the degree of platelet inhibition achieved by this novel tirofiban dosing strategy was assessed."( High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S, 2008
)
0.98
" This dosing during PCI appears safe and compares favorably with eptifibatide bolus-only during PCI."( High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
Agarwal, A; Cavusoglu, E; Manjappa, N; Marmur, JD; Poludasu, S, 2008
)
0.75
" Interestingly, the patient underwent a percutaneous coronary intervention 1 month before and received the same dosage regimen of tirofiban without complications."( [Acute profound thrombocytopenia associated with tirofiban: clinical approach to diagnosis and therapeutic management].
Agnelli, D; Ottani, F, 2008
)
0.81
" Tirofiban and eptifibatide are renally cleared and thus must have dosage adjustment if used in patients with renal insufficiency (RI)."( Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
Anderson, JR; Riding, D,
)
1.04
" Of particular interest is the optimal dosing of glycoprotein IIb-IIIa inhibitors in the setting of acute myocardial infarction."( In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
Alam, M; Bobek, J; Delarosa, A; Dokainish, H; Gonzalez, R; Lakkis, N, 2009
)
0.58
"We suggest further clinical trials to define an objective means to calculate proper renal dosing of glycoprotein IIb-IIIa inhibitors in these patients to prevent potentially fatal complication of major hemorrhagic events."( In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
Alam, M; Bobek, J; Delarosa, A; Dokainish, H; Gonzalez, R; Lakkis, N, 2009
)
0.58
" Additionally, it provides an overview of tirofiban's pharmacology and summary of the clinical efficacy and safety data of two dosing regimens."( Safety evaluation of tirofiban.
Tebaldi, M; Valgimigli, M, 2010
)
0.94
" The objective of the present study was to use pharmacokinetic modeling to identify an appropriate dosage of tirofiban that would produce a plasma concentration-time profile in patients with severe renal impairment (creatinine clearance<30 ml/min) as similar as possible to that of the HDB regimen in patients with normal renal function."( Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
Janzen, MC; Lakings, DB; Schneider, DJ, 2012
)
0.83
"To explore the optimal dosage of tirofiban associated with double benefits of efficacy and safety in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) undergoing early percutaneous coronary intervention (PCI)."( Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Wang, X; Wang, Y; Wu, W; Xue, H; Yang, Z; Zhao, Y, 2013
)
0.92
" All patients received low-molecular-weight heparin in prophylactic dosage starting 24 hours after aneurysm treatment."( Ventriculostomy-Related Hemorrhage After Treatment of Acutely Ruptured Aneurysms: The Influence of Anticoagulation and Antiplatelet Treatment.
Bruder, M; El-Fiki, A; Güresir, E; Konczalla, J; Lescher, S; Schuss, P; Seifert, V; Vatter, H, 2015
)
0.42
" Tirofiban, in particular, fell out of favor due to inferior dosing with its original Food and Drug Administration (FDA) approved indication, but has re-emerged in the market with a high-dose bolus regimen that is considered equally as effective as the FDA approved dosing regimens of other GP IIb/IIIa inhibitors."( Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Harmon, C; King, S; Short, M, 2016
)
1.6
" This review provides a comprehensive evaluation of the current published literature pertaining to the use of all available GP IIb/IIIa inhibitors for thromboembolic complications, providing recommendations for dosing and administration of abciximab, eptifibatide, and tirofiban based on previously published rates of efficacy and intracranial hemorrhage."( Glycoprotein IIb/IIIa Inhibitors in Prevention and Rescue Treatment of Thromboembolic Complications During Endovascular Embolization of Intracranial Aneurysms.
Dornbos, D; Katz, JS; Nimjee, SM; Powers, CJ; Youssef, P, 2018
)
0.66
" A tirofiban infusion without bolus dosing may be a safe option for antiplatelet bridging in patients with a recent cardiac stent implant to prevent stent thrombosis."( Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis.
Dager, WE; Walker, EA, 2017
)
1.44
" Therefore, the rational dosage application of tirofiban become much indispensable in view of patient's conditions and hemorrhagic risk, and a medium dose of 10 μg/kg may be appropriate for patients without high hemorrhagic risk."( Influences of different dose of tirofiban for acute ST elevation myocardial infarction patients underwent percutaneous coronary intervention.
Feng, M; Wang, H, 2020
)
1.1
" However, there are few comparative studies of a reasonable dosage for the prophylactic use of tirofiban."( The safety and efficacy of low-dosage tirofiban for stent-assisted coiling of ruptured intracranial aneurysms.
Fang, Y; He, X; Hong, B; Huang, Q; Liu, J; Xu, Y; Yan, Y, 2021
)
1.11
" However, the safety and efficacy of optimal dosage and the reasonable treatment course of tirofiban have not been determined."( Safety and efficacy of intravenous tirofiban for stent-assisted coiling in acutely ruptured intracranial aneurysms: A single center experience.
Chen, X; Feng, Y; Jia, C; Ma, Y; Zhang, T; Zhao, W, 2022
)
1.22
" However, the dosage recommendations in the United States (US) and European Union (EU) differ considerably."( Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.
Gurbel, PA; Heramvand, N; Jung, C; Karathanos, A; Kelm, M; Masyuk, M; Muessig, JM; Nia, AM; Polzin, A; Tantry, US; Valgimigli, M, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
fibrin modulating drugA drug that affects the function of fibrin in blood coagulation.
platelet glycoprotein-IIb/IIIa receptor antagonistAntagonist of platelet surface glycoprotein-IIb/IIIa which has a key role in hemostasis and thrombosis such as platelet adhesion and aggregation.
anticoagulantAn agent that prevents blood clotting.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
piperidines
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
L-tyrosine derivativeA proteinogenic amino acid derivative resulting from reaction of L-tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tyrosine by a heteroatom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin subunit alpha 2bRattus norvegicus (Norway rat)IC50 (µMol)0.13000.13000.13000.1300AID1756227
Integrin beta-3Homo sapiens (human)IC50 (µMol)21.44370.00010.632310.0000AID1159175; AID1159180; AID1251257; AID1251259; AID1290546; AID1337713; AID1576816; AID161600; AID1647696; AID1667330; AID1686185; AID1686204; AID1744039; AID217295; AID217306; AID222789; AID225586; AID32990; AID645256; AID649223; AID730659; AID73151; AID73156; AID753175; AID761290; AID84810; AID84812; AID84830; AID93006; AID93153
Integrin beta-1Homo sapiens (human)IC50 (µMol)300.00000.00010.72528.0000AID221747; AID84811
Integrin alpha-V Homo sapiens (human)IC50 (µMol)113.83520.00010.625610.0000AID1647696; AID217295; AID217306; AID84810; AID84812; AID84830
Integrin alpha-IIbHomo sapiens (human)IC50 (µMol)0.12250.00010.730910.0000AID1159175; AID1159180; AID1251257; AID1251259; AID1290546; AID1337713; AID1576816; AID161600; AID1667330; AID1686185; AID1686204; AID1744039; AID222789; AID225586; AID32990; AID645256; AID649223; AID730659; AID73151; AID73156; AID753175; AID761290; AID93006; AID93153
Integrin alpha-5Homo sapiens (human)IC50 (µMol)300.00000.00011.40828.0000AID221747; AID84811
Integrin beta-3 Rattus norvegicus (Norway rat)IC50 (µMol)0.13000.13000.13000.1300AID1756227
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin beta-3Homo sapiens (human)Kd0.01000.00010.11780.6500AID220877; AID220879; AID73144
Integrin alpha-IIbHomo sapiens (human)Kd0.01000.00010.12430.6500AID220877; AID220879; AID73144
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin beta-3Homo sapiens (human)ED500.00100.00010.00200.0050AID73143
Integrin alpha-IIbHomo sapiens (human)ED500.00100.00010.00200.0050AID73143
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayIntegrin beta-1Homo sapiens (human)
stress fiber assemblyIntegrin beta-1Homo sapiens (human)
calcium-independent cell-matrix adhesionIntegrin beta-1Homo sapiens (human)
positive regulation of apoptotic processIntegrin beta-1Homo sapiens (human)
positive regulation of glutamate uptake involved in transmission of nerve impulseIntegrin beta-1Homo sapiens (human)
regulation of inward rectifier potassium channel activityIntegrin beta-1Homo sapiens (human)
regulation of spontaneous synaptic transmissionIntegrin beta-1Homo sapiens (human)
reactive gliosisIntegrin beta-1Homo sapiens (human)
G1/S transition of mitotic cell cycleIntegrin beta-1Homo sapiens (human)
establishment of mitotic spindle orientationIntegrin beta-1Homo sapiens (human)
in utero embryonic developmentIntegrin beta-1Homo sapiens (human)
cell migration involved in sprouting angiogenesisIntegrin beta-1Homo sapiens (human)
positive regulation of neuroblast proliferationIntegrin beta-1Homo sapiens (human)
phagocytosisIntegrin beta-1Homo sapiens (human)
cellular defense responseIntegrin beta-1Homo sapiens (human)
cell adhesionIntegrin beta-1Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesIntegrin beta-1Homo sapiens (human)
leukocyte cell-cell adhesionIntegrin beta-1Homo sapiens (human)
cell-matrix adhesionIntegrin beta-1Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-1Homo sapiens (human)
neuroblast proliferationIntegrin beta-1Homo sapiens (human)
muscle organ developmentIntegrin beta-1Homo sapiens (human)
myoblast fusionIntegrin beta-1Homo sapiens (human)
germ cell migrationIntegrin beta-1Homo sapiens (human)
visual learningIntegrin beta-1Homo sapiens (human)
regulation of collagen catabolic processIntegrin beta-1Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-1Homo sapiens (human)
cell migrationIntegrin beta-1Homo sapiens (human)
formation of radial glial scaffoldsIntegrin beta-1Homo sapiens (human)
CD40 signaling pathwayIntegrin beta-1Homo sapiens (human)
cell projection organizationIntegrin beta-1Homo sapiens (human)
lamellipodium assemblyIntegrin beta-1Homo sapiens (human)
B cell differentiationIntegrin beta-1Homo sapiens (human)
extracellular matrix organizationIntegrin beta-1Homo sapiens (human)
positive regulation of cell migrationIntegrin beta-1Homo sapiens (human)
cell-substrate adhesionIntegrin beta-1Homo sapiens (human)
receptor internalizationIntegrin beta-1Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-1Homo sapiens (human)
cell-cell adhesion mediated by integrinIntegrin beta-1Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-1Homo sapiens (human)
negative regulation of Rho protein signal transductionIntegrin beta-1Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-1Homo sapiens (human)
maintenance of blood-brain barrierIntegrin beta-1Homo sapiens (human)
positive regulation of GTPase activityIntegrin beta-1Homo sapiens (human)
sarcomere organizationIntegrin beta-1Homo sapiens (human)
myoblast differentiationIntegrin beta-1Homo sapiens (human)
negative regulation of neuron differentiationIntegrin beta-1Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwayIntegrin beta-1Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-1Homo sapiens (human)
negative regulation of vasoconstrictionIntegrin beta-1Homo sapiens (human)
symbiont entry into host cellIntegrin beta-1Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-1Homo sapiens (human)
myoblast fate specificationIntegrin beta-1Homo sapiens (human)
axon extensionIntegrin beta-1Homo sapiens (human)
dendrite morphogenesisIntegrin beta-1Homo sapiens (human)
leukocyte tethering or rollingIntegrin beta-1Homo sapiens (human)
regulation of cell cycleIntegrin beta-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionIntegrin beta-1Homo sapiens (human)
cardiac muscle cell differentiationIntegrin beta-1Homo sapiens (human)
cardiac muscle cell myoblast differentiationIntegrin beta-1Homo sapiens (human)
cardiac cell fate specificationIntegrin beta-1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusIntegrin beta-1Homo sapiens (human)
basement membrane organizationIntegrin beta-1Homo sapiens (human)
positive regulation of wound healingIntegrin beta-1Homo sapiens (human)
positive regulation of vascular endothelial growth factor signaling pathwayIntegrin beta-1Homo sapiens (human)
positive regulation of protein localization to plasma membraneIntegrin beta-1Homo sapiens (human)
regulation of synapse pruningIntegrin beta-1Homo sapiens (human)
negative regulation of anoikisIntegrin beta-1Homo sapiens (human)
cell-cell adhesionIntegrin beta-1Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin alpha-V Homo sapiens (human)
angiogenesisIntegrin alpha-V Homo sapiens (human)
vasculogenesisIntegrin alpha-V Homo sapiens (human)
cell adhesionIntegrin alpha-V Homo sapiens (human)
cell-matrix adhesionIntegrin alpha-V Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationIntegrin alpha-V Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
positive regulation of cell population proliferationIntegrin alpha-V Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid storageIntegrin alpha-V Homo sapiens (human)
cell migrationIntegrin alpha-V Homo sapiens (human)
positive regulation of cell migrationIntegrin alpha-V Homo sapiens (human)
cell-substrate adhesionIntegrin alpha-V Homo sapiens (human)
negative regulation of lipid transportIntegrin alpha-V Homo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-V Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin alpha-V Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin alpha-V Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin alpha-V Homo sapiens (human)
endodermal cell differentiationIntegrin alpha-V Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin alpha-V Homo sapiens (human)
apoptotic cell clearanceIntegrin alpha-V Homo sapiens (human)
positive regulation of cell adhesionIntegrin alpha-V Homo sapiens (human)
symbiont entry into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin alpha-V Homo sapiens (human)
regulation of phagocytosisIntegrin alpha-V Homo sapiens (human)
negative chemotaxisIntegrin alpha-V Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionIntegrin alpha-V Homo sapiens (human)
ERK1 and ERK2 cascadeIntegrin alpha-V Homo sapiens (human)
calcium ion transmembrane transportIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta productionIntegrin alpha-V Homo sapiens (human)
entry into host cell by a symbiont-containing vacuoleIntegrin alpha-V Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandIntegrin alpha-V Homo sapiens (human)
positive regulation of intracellular signal transductionIntegrin alpha-V Homo sapiens (human)
negative regulation of entry of bacterium into host cellIntegrin alpha-V Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayIntegrin alpha-V Homo sapiens (human)
cell-cell adhesionIntegrin alpha-V Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-5Homo sapiens (human)
cell-substrate junction assemblyIntegrin alpha-5Homo sapiens (human)
cell adhesionIntegrin alpha-5Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesIntegrin alpha-5Homo sapiens (human)
leukocyte cell-cell adhesionIntegrin alpha-5Homo sapiens (human)
cell-matrix adhesionIntegrin alpha-5Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-5Homo sapiens (human)
female pregnancyIntegrin alpha-5Homo sapiens (human)
memoryIntegrin alpha-5Homo sapiens (human)
positive regulation of cell-substrate adhesionIntegrin alpha-5Homo sapiens (human)
CD40 signaling pathwayIntegrin alpha-5Homo sapiens (human)
positive regulation of cell migrationIntegrin alpha-5Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin alpha-5Homo sapiens (human)
cell-substrate adhesionIntegrin alpha-5Homo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-5Homo sapiens (human)
cell-cell adhesion mediated by integrinIntegrin alpha-5Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin alpha-5Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin alpha-5Homo sapiens (human)
endodermal cell differentiationIntegrin alpha-5Homo sapiens (human)
symbiont entry into host cellIntegrin alpha-5Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin alpha-5Homo sapiens (human)
positive regulation of sprouting angiogenesisIntegrin alpha-5Homo sapiens (human)
negative regulation of anoikisIntegrin alpha-5Homo sapiens (human)
cell-cell adhesionIntegrin alpha-5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-1Homo sapiens (human)
magnesium ion bindingIntegrin beta-1Homo sapiens (human)
virus receptor activityIntegrin beta-1Homo sapiens (human)
fibronectin bindingIntegrin beta-1Homo sapiens (human)
protease bindingIntegrin beta-1Homo sapiens (human)
actin bindingIntegrin beta-1Homo sapiens (human)
integrin bindingIntegrin beta-1Homo sapiens (human)
calcium ion bindingIntegrin beta-1Homo sapiens (human)
protein bindingIntegrin beta-1Homo sapiens (human)
coreceptor activityIntegrin beta-1Homo sapiens (human)
protein-containing complex bindingIntegrin beta-1Homo sapiens (human)
cadherin bindingIntegrin beta-1Homo sapiens (human)
protein heterodimerization activityIntegrin beta-1Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-1Homo sapiens (human)
collagen binding involved in cell-matrix adhesionIntegrin beta-1Homo sapiens (human)
integrin binding involved in cell-matrix adhesionIntegrin beta-1Homo sapiens (human)
protein tyrosine kinase bindingIntegrin beta-1Homo sapiens (human)
protein kinase bindingIntegrin beta-1Homo sapiens (human)
laminin bindingIntegrin beta-1Homo sapiens (human)
opsonin bindingIntegrin alpha-V Homo sapiens (human)
protein kinase C bindingIntegrin alpha-V Homo sapiens (human)
fibroblast growth factor bindingIntegrin alpha-V Homo sapiens (human)
C-X3-C chemokine bindingIntegrin alpha-V Homo sapiens (human)
insulin-like growth factor I bindingIntegrin alpha-V Homo sapiens (human)
neuregulin bindingIntegrin alpha-V Homo sapiens (human)
virus receptor activityIntegrin alpha-V Homo sapiens (human)
fibronectin bindingIntegrin alpha-V Homo sapiens (human)
protease bindingIntegrin alpha-V Homo sapiens (human)
integrin bindingIntegrin alpha-V Homo sapiens (human)
voltage-gated calcium channel activityIntegrin alpha-V Homo sapiens (human)
protein bindingIntegrin alpha-V Homo sapiens (human)
coreceptor activityIntegrin alpha-V Homo sapiens (human)
metal ion bindingIntegrin alpha-V Homo sapiens (human)
transforming growth factor beta bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix bindingIntegrin alpha-V Homo sapiens (human)
extracellular matrix protein bindingIntegrin alpha-V Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
virus receptor activityIntegrin alpha-5Homo sapiens (human)
epidermal growth factor receptor bindingIntegrin alpha-5Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin alpha-5Homo sapiens (human)
calcium ion bindingIntegrin alpha-5Homo sapiens (human)
protein bindingIntegrin alpha-5Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin alpha-5Homo sapiens (human)
integrin bindingIntegrin alpha-5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (70)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-1Homo sapiens (human)
ruffle membraneIntegrin beta-1Homo sapiens (human)
ruffleIntegrin beta-1Homo sapiens (human)
cytoplasmIntegrin beta-1Homo sapiens (human)
plasma membraneIntegrin beta-1Homo sapiens (human)
focal adhesionIntegrin beta-1Homo sapiens (human)
external side of plasma membraneIntegrin beta-1Homo sapiens (human)
cell surfaceIntegrin beta-1Homo sapiens (human)
endosome membraneIntegrin beta-1Homo sapiens (human)
intercalated discIntegrin beta-1Homo sapiens (human)
membraneIntegrin beta-1Homo sapiens (human)
lamellipodiumIntegrin beta-1Homo sapiens (human)
filopodiumIntegrin beta-1Homo sapiens (human)
neuromuscular junctionIntegrin beta-1Homo sapiens (human)
cleavage furrowIntegrin beta-1Homo sapiens (human)
ruffle membraneIntegrin beta-1Homo sapiens (human)
integrin alpha1-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha2-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha4-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha5-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha6-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha9-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha10-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alphav-beta1 complexIntegrin beta-1Homo sapiens (human)
myelin sheath abaxonal regionIntegrin beta-1Homo sapiens (human)
sarcolemmaIntegrin beta-1Homo sapiens (human)
melanosomeIntegrin beta-1Homo sapiens (human)
dendritic spineIntegrin beta-1Homo sapiens (human)
membrane raftIntegrin beta-1Homo sapiens (human)
perinuclear region of cytoplasmIntegrin beta-1Homo sapiens (human)
recycling endosomeIntegrin beta-1Homo sapiens (human)
extracellular exosomeIntegrin beta-1Homo sapiens (human)
synaptic membraneIntegrin beta-1Homo sapiens (human)
glial cell projectionIntegrin beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseIntegrin beta-1Homo sapiens (human)
cerebellar climbing fiber to Purkinje cell synapseIntegrin beta-1Homo sapiens (human)
integrin alpha3-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha7-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha8-beta1 complexIntegrin beta-1Homo sapiens (human)
integrin alpha11-beta1 complexIntegrin beta-1Homo sapiens (human)
receptor complexIntegrin beta-1Homo sapiens (human)
focal adhesionIntegrin beta-1Homo sapiens (human)
synapseIntegrin beta-1Homo sapiens (human)
integrin complexIntegrin beta-1Homo sapiens (human)
cell surfaceIntegrin beta-1Homo sapiens (human)
cytosolIntegrin alpha-V Homo sapiens (human)
plasma membraneIntegrin alpha-V Homo sapiens (human)
focal adhesionIntegrin alpha-V Homo sapiens (human)
cell surfaceIntegrin alpha-V Homo sapiens (human)
membraneIntegrin alpha-V Homo sapiens (human)
lamellipodium membraneIntegrin alpha-V Homo sapiens (human)
filopodium membraneIntegrin alpha-V Homo sapiens (human)
microvillus membraneIntegrin alpha-V Homo sapiens (human)
ruffle membraneIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta1 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta3 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta5 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta6 complexIntegrin alpha-V Homo sapiens (human)
integrin alphav-beta8 complexIntegrin alpha-V Homo sapiens (human)
specific granule membraneIntegrin alpha-V Homo sapiens (human)
phagocytic vesicleIntegrin alpha-V Homo sapiens (human)
extracellular exosomeIntegrin alpha-V Homo sapiens (human)
integrin complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin alpha-V Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin alpha-V Homo sapiens (human)
external side of plasma membraneIntegrin alpha-V Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cell-cell junctionIntegrin alpha-5Homo sapiens (human)
focal adhesionIntegrin alpha-5Homo sapiens (human)
ruffle membraneIntegrin alpha-5Homo sapiens (human)
ruffleIntegrin alpha-5Homo sapiens (human)
endoplasmic reticulumIntegrin alpha-5Homo sapiens (human)
Golgi apparatusIntegrin alpha-5Homo sapiens (human)
plasma membraneIntegrin alpha-5Homo sapiens (human)
focal adhesionIntegrin alpha-5Homo sapiens (human)
cell surfaceIntegrin alpha-5Homo sapiens (human)
cytoplasmic vesicleIntegrin alpha-5Homo sapiens (human)
integrin alpha5-beta1 complexIntegrin alpha-5Homo sapiens (human)
postsynaptic membraneIntegrin alpha-5Homo sapiens (human)
glutamatergic synapseIntegrin alpha-5Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin alpha-5Homo sapiens (human)
external side of plasma membraneIntegrin alpha-5Homo sapiens (human)
integrin complexIntegrin alpha-5Homo sapiens (human)
plasma membraneIntegrin beta-3 Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (113)

Assay IDTitleYearJournalArticle
AID84811Inhibition of HUVEC attachment to human fibronectin1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
AID1686189Toxicity in human HT-29 cells assessed as induction of cell necrosis and/or apoptosis incubated for 3 hrs by annexin V-PE and 7-AAD staining based by flow cytometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID73156Inhibition of [125I]fibrinogen binding to fibrinogen receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
AID1686187Toxicity in human SK-MEL-24 cells assessed as induction of cell necrosis and/or apoptosis incubated for 3 hrs by annexin V-PE and 7-AAD staining based by flow cytometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1576816Inhibition of human fibronectin binding to human Integrin alpha2b beta3 receptor incubated for 1 hr by ELISA2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.
AID73143In vitro inhibition of [125I]L-692884 binding to Fibrinogen receptor by silicate scintillation proximity assay(SPA)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
AID161600Inhibition of platelet aggregation as the concentration necessary to inhibit the change in light. 1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID222789Inhibition of aggregation of human gel-filtered platelets measured by light transmittance method at 37 degrees C.2000Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.
AID1686202Agonist activity at alpha4beta1 in human Jurkat E6.1 cells assessed as increase in cell adhesion to VCAM1 pre-incubated for 30 mins before VCAM1 and further incubated for 30 mins by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic ass2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1251258Antagonist activity against integrin alpha2bbeta3 open form in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID1686206Agonist activity at alphaLbeta2 in human Jurkat E6.1 cells assessed as increase in cell adhesion to ICAM1 pre-incubated for 30 mins before ICAM1 and further incubated for 30 mins by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic ass2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686190Toxicity in human K562 cells assessed as induction of cell necrosis and/or apoptosis incubated for 3 hrs by annexin V-PE and 7-AAD staining based by flow cytometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686185Inhibition of fibrinogen binding to alpha2bbeta3 isolated from human HEL cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1337717Toxicity in ICR mouse assessed as bleeding time at 1 mg/kg, iv administered 30 mins prior to test by tail transection method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
AID220879Competition with [1251]L-692,884 for binding to purified alpha IIb/beta3 integrin, activated by coating onto yttrium silicate scintillation proximity assay fluomicrospheres.2000Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.
AID1251263Drug level in healthy human subjects2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID84812Inhibition of HUVEC attachment to human vitronectin1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
AID84810Inhibition of HUVEC attachment to human fibrinogen1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
AID84830Inhibition of human umbilical vein endothelial cell adhesion to fibrinogen1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
AID753176Inhibition of trypsin (unknown origin) using S-2222 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis2013European journal of medicinal chemistry, Jun, Volume: 64Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID753175Displacement of biotinylated fibrinogen from human glycoprotein 2b/3a receptor after 2 hrs by chemiluminescence assay2013European journal of medicinal chemistry, Jun, Volume: 64Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID730659Inhibition of fibrinogen binding to Integrin alpha2bbeta3 receptor (unknown origin) by competitive ELISA2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.
AID1686208Inhibition of fibronectin binding to human recombinant alphaVbeta3 expressed in HEK293 cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1576815Inhibition of human fibronectin binding to human integrin alpha5beta1 incubated for 1 hr by ELISA2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.
AID1251260Antagonist activity against integrin alpha2bbeta3 closed form in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID1686193Antagonist activity at alphaVbeta3 in human SK-MEL-24 cells assessed as reduction in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chro2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID93006In vitro inhibition of ADP-mediated human gel filtered platelet aggregation.1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.
AID1576814Inhibition of human vitronectin binding to human integrin alphavbeta3 receptor after 1 hr by ELISA2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.
AID1337709Antagonist activity at GP2b/GP3a receptor in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation preincubated for 1 min followed by ADP addition by aggregometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
AID1686199Antagonist activity at alphaVbeta6 in human HT-29 cells assessed as reduction in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromoge2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1250225Toxicity in ICR mouse assessed as bleeding time at 1 mg/kg incubated for 30 mins prior to testing by tail transection method2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1686188Toxicity in human MCF7 cells assessed as induction of cell necrosis and/or apoptosis incubated for 3 hrs by annexin V-PE and 7-AAD staining based by flow cytometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID217295Inhibition of human umbilical vein endothelial cell adhesion to vitronectin1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1250220Antagonist activity at GP2b/3a receptor in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1 to 1000 uM preincubated for 1 min followed by addition of ADP by aggregometer2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).
AID1337720Anti-thrombotic activity in Sprague-Dawley rat arterio-venous shunt thrombosis model assessed as reduction in thrombus weight at 1 mg/kg, iv pretreated for 15 mins followed by arteriovenous shunt thrombosis induction measured after 20 mins relative to con2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
AID221747Inhibition of human umbilical vein endothelial cell adhesion to fibronectin1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
AID1686201Antagonist activity at alpha5beta1 in human K562 cells assessed as reduction in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogen2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID217306Inhibition of binding to human Vitronectin receptor (integrin alphaV-beta3)2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Molecular model of the alpha(IIb)beta(3) integrin.
AID1756227Inhibition of fibrinogen binding to rat platelet integrin alpha2b beta3 by ELISA based solid phase binding assay
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1290546Inhibition of FITC-labelled fibrinogen binding to integrin alpha2b beta3 receptor in human platelet cells2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.
AID753177Inhibition of thrombin (unknown origin) using S-2238 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis2013European journal of medicinal chemistry, Jun, Volume: 64Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID73144Equilibrium dissociation constant was measured from displacement of L-762,745 from Fibrinogen receptor of human platelets by flow cytometry1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID649223Displacement of extracellular matrix protein fibrinogen from human integrin alpha2bbeta3 after 1 hr by competitive ELISA2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.
AID32990Inhibition of human alphaIIb-beta3 integrin in platelet aggregation assay2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Molecular model of the alpha(IIb)beta(3) integrin.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1686198Agonist activity at alphaVbeta6 in human HT-29 cells assessed as increase in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic 2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1744038Binding affinity to human integrin alphaVbeta8 incubated for 1 hr by ELISA based solid phase integrin binding assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.
AID649224Inhibition of integrin alpha2bbeta3-mediated platelet aggregation in human TRAP-6-activated whole blood for 6 mins by impedence-based aggregometry2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.
AID1686207Antagonist activity at alphaLbeta2 in human Jurkat E6.1 cells assessed as reduction in cell adhesion to ICAM1 pre-incubated for 30 mins before ICAM1 and further incubated for 30 mins by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686196Agonist activity at alphaVbeta5 in human MCF7 cells assessed as increase in cell adhesion to fibrinogen pre-incubated for 30 mins before fibrinogen and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic ass2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID645256Displacement of biotinylated fibrinogen from human alpha2b-beta3 receptor after 2 hrs by chemiluminescence assay2012European journal of medicinal chemistry, Apr, Volume: 50Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1069980Inhibition of alpha2beta3 receptor (unknown origin) assessed as inhibition of platelet adhesion at 10 uM2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.
AID1686210Inhibition of fibronectin binding to alphaVbeta6 isolated form human HT-29 cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID73151Compound was evaluated for inhibition against Fibrinogen Receptor.1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1686200Agonist activity at alpha5beta1 in human K562 cells assessed as increase in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic a2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686204Antagonist activity at alpha2bbeta3 in human HEL cells assessed as reduction in cell adhesion to fibrinogen pre-incubated for 30 mins before fibrinogen and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1744039Binding affinity to human integrin alpha2bbeta3 incubated for 1 hr by ELISA based solid phase integrin binding assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.
AID1686205Antagonist activity at alpha4beta1 in human Jurkat E6.1 cells assessed as reduction in cell adhesion to VCAM1 pre-incubated for 30 mins before VCAM1 and further incubated for 30 mins by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686211Inhibition of fibronectin binding to alpha4bbeta1 isolated from human Jurkat E6.1 cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID649225Apparent permeability across human Caco2 cells after 30 to 150 mins2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.
AID1250228Antithrombotic activity in Sprague-Dawley rat arteriovenous shunt thrombosis model assessed as wet/dry weight reduction of thrombus at 1 mg/kg, iv incubated for 30 mins prior to testing2015European journal of medicinal chemistry, Sep-18, Volume: 102Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp).
AID1686209Inhibition of fibrinogen binding to alphaVbeta5 isolated form human mCf7 cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID753178Inhibition of F10a (unknown origin) using S-2222 as substrate incubated for 15 mins prior to substrate addition measured every 10 secs by spectrophotometric analysis2013European journal of medicinal chemistry, Jun, Volume: 64Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
AID1251259Inhibition of FITC-labeled fibrinogen binding to integrin alpha2bbeta3 closed form in human washed platelets2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID220877Binding affinity to resting form of alpha IIb/beta3 integrin by flow cytometry using fluorescein ligand L-726,745 displacement from human platelets.2000Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1686197Antagonist activity at alphaVbeta5 in human MCF7 cells assessed as reduction in cell adhesion to fibrinogen pre-incubated for 30 mins before fibrinogen and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromogenic2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1337713Displacement of fibrinogen from human platelet GP2b/GP3a receptor after 2 hrs by ELISA2017European journal of medicinal chemistry, Jan-05, Volume: 125Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.
AID225586Inhibition of platelet aggregation2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
AID1159180Binding affinity to alpha2b/beta3 integrin (unknown origin)2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1159175Inhibition of fibrinogen binding to human alpha2b/beta3 integrin after 1 hr by ELISA2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
AID730661Inhibition of vitronectin binding to Integrin alphaVbeta5 receptor (unknown origin) by competitive ELISA2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1251257Inhibition of FITC-labeled fibrinogen binding to integrin alpha2bbeta3 open form in human washed platelets2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID1744037Binding affinity to human integrin alphaVbeta6 incubated for 1 hr by ELISA based solid phase integrin binding assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.
AID1667330Inhibition of fibrinogen binding to human platelet integrin alpha2b beta3 by ELISA based solid phase binding assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Novel cilengitide-based cyclic RGD peptides as αvβ
AID24332half-life of compound in human2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
AID761291Inhibition of ADP-induced human platelet aggregation in platelet-rich plasma by Born's method2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.
AID93153The compound was tested in vivo for the inhibition of aggregation of human gel-filtered platelets(GFP)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
AID1576813Binding affinity to integrin alphavbeta3 receptor in human WM115 cells assessed as inhibition of cell adhesion to vitronectin after 0.5 hr by fluorescence assay2019Journal of medicinal chemistry, 08-22, Volume: 62, Issue:16
Cyclization of RGD Peptides by Suzuki-Miyaura Cross-Coupling.
AID730660Inhibition of latency-associated peptide binding to Integrin alphaVbeta6 receptor (unknown origin) by competitive ELISA2013Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4
Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids.
AID1686191Toxicity in human HEL cells assessed as induction of cell necrosis and/or apoptosis incubated for 3 hrs by annexin V-PE and 7-AAD staining based by flow cytometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID233840Selectivity as determined by the ratio of KDs, resting receptor over activated receptor2000Bioorganic & medicinal chemistry letters, Sep-04, Volume: 10, Issue:17
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1647696Inhibition of human integrin alphavbeta3 (unknown origin)2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1290545Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation by Born's method2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.
AID1686192Agonist activity at alphaVbeta3 in human SK-MEL-24 cells assessed as increase in cell adhesion to fibronectin pre-incubated for 30 mins before fibronectin and further incubated for 1 hr by nitrophenyl-N-acetyl-beta-D-glucosaminide substrate based chromoge2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID1686186Inhibition of fibronectin binding to alpha5beta1 isolated from human K562 cells incubated for 1 hr by scintillation-proximity assay based competitive solid-phase binding assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins.
AID761290Inhibition of FITC-labeled fibrinogen binding to integrin alpha2bbeta3 receptor in human platelets by flow cytometry2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,156)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's96 (8.30)18.2507
2000's594 (51.38)29.6817
2010's323 (27.94)24.3611
2020's143 (12.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.24 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index123.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials309 (25.54%)5.53%
Reviews201 (16.61%)6.00%
Case Studies142 (11.74%)4.05%
Observational18 (1.49%)0.25%
Other540 (44.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (53)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Reduction of Microembolism After Stent-Assisted Coil Embolization of Unruptured Intracranial Aneurysms by Administration of Tirofiban:A Randomized, Controlled, Double-blind Trial [NCT05841147]Phase 470 participants (Anticipated)Interventional2023-04-25Recruiting
Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS [NCT00713557]20,000 participants (Anticipated)Observational2005-03-31Terminated(stopped due to devices applied in the study were no more available in the market, and medical intervention section was completed.)
Comparison of Multiple Oral and/or Intravenous Anti-platelet Strategies in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary PCI [NCT01336348]Phase 3100 participants (Anticipated)Interventional2010-04-30Completed
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients [NCT01181388]200 participants (Anticipated)Interventional2010-04-30Recruiting
Effectiveness of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT02054000]Phase 4162 participants (Actual)Interventional2011-01-31Completed
A Phase 1/2a Exploratory Clinical Trial: Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM) [NCT03691727]Phase 1/Phase 230 participants (Actual)Interventional2019-01-24Completed
A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON [NCT02131220]Phase 4362 participants (Actual)Interventional2015-11-30Completed
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial [NCT05611242]Phase 3404 participants (Anticipated)Interventional2023-11-01Recruiting
Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty. [NCT00566891]Phase 42,000 participants (Actual)Interventional2007-12-31Completed
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT06045156]1,084 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Prevention of Coronary Slow Flow or No-Reflow During Elective Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction [NCT03406832]1,000 participants (Anticipated)Interventional2018-01-08Recruiting
Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease [NCT02294994]Phase 41,000 participants (Anticipated)Interventional2014-11-30Recruiting
Prospective Randomized Controlled Clinical Study to Compare Tirofiban Intracoronary Bolus-Only vs Intravenous Bolus Plus Infusion in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention [NCT01109134]Phase 349 participants (Actual)Interventional2008-09-30Completed
Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome [NCT04111289]Phase 1/Phase 2150 participants (Anticipated)Interventional2019-11-01Not yet recruiting
Early Initiation of Low Dose Tirofiban for Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction. [NCT03797729]Phase 4500 participants (Anticipated)Interventional2019-05-14Recruiting
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Intravenous Thrombolytic Therapy With Alteplase in Acute Ischemic Stroke [NCT05188417]Phase 2266 participants (Actual)Interventional2021-12-09Active, not recruiting
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in ST-elevation Myocardial Infarction Patients Treated With Primary Angioplasty [NCT02592694]Phase 41,000 participants (Anticipated)Interventional2015-10-31Recruiting
High Bolus Dose Tirofiban and Enoxaparin Provides Reduced Thrombin Generation and Inflammatory Markers in Patients With High Risk Undergoing Percutaneous Intervention [NCT00790387]Phase 460 participants (Actual)Interventional2004-06-30Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention [NCT01245725]Phase 30 participants (Actual)InterventionalWithdrawn(stopped due to Study was not initiated, change in clinical development)
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention [NCT00407771]Phase 444 participants (Anticipated)Interventional2007-11-30Not yet recruiting
Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment [NCT05225961]Phase 4240 participants (Anticipated)Interventional2022-05-01Recruiting
Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT) [NCT06134622]Phase 3832 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT) [NCT06037889]Phase 3516 participants (Anticipated)Interventional2023-11-09Recruiting
Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) [NCT02592720]Phase 4500 participants (Anticipated)Interventional2015-10-31Recruiting
The Effects of Facilitated Percutaeous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction [NCT00611169]Phase 440 participants (Actual)Interventional2006-01-31Completed
Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial [NCT00229515]Phase 4744 participants (Actual)Interventional2004-11-30Active, not recruiting
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel [NCT00398463]Phase 4263 participants (Actual)Interventional2006-05-31Completed
FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study [NCT00383136]Phase 4692 participants (Actual)Interventional2003-06-30Completed
A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention [NCT01103440]Phase 236 participants (Actual)Interventional2007-04-30Completed
Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty [NCT00538317]Phase 4320 participants (Actual)Interventional2007-07-31Completed
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial [NCT02978040]Phase 4122 participants (Actual)Interventional2017-07-04Completed
[NCT00300833]Phase 4200 participants (Anticipated)Interventional2006-01-31Recruiting
Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent [NCT01498003]Phase 4748 participants (Actual)Interventional2011-11-30Completed
Intravenous Adjuvant With Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Acute Ischemic Stroke Patients With Large Vessel Occlusion: a Multicenter, Open Label, Randomized Controlled Trial. [NCT05728333]Phase 2/Phase 3800 participants (Anticipated)Interventional2023-03-01Not yet recruiting
Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study [NCT01660373]Phase 3100 participants (Anticipated)Interventional2012-08-31Recruiting
A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention [NCT01522417]Phase 2535 participants (Actual)Interventional2012-04-30Completed
Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial [NCT01696110]Phase 42,194 participants (Actual)Interventional2012-08-31Completed
A Pharmacokinetic, Pharmacodynamic, and Safety Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Normal Renal Function and Subjects With Moderate-to-Severe Renal Impairment With Non-Dialysis-Dependent Renal Insufficiency (NDDRI) [NCT01766154]Phase 125 participants (Actual)Interventional2013-01-31Completed
Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol [NCT04368377]Phase 25 participants (Actual)Interventional2020-04-06Completed
Safety and Efficacy of Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke [NCT05604638]Phase 4600 participants (Anticipated)Interventional2023-03-31Not yet recruiting
Treatment by Anti GP IIb/IIIa in the Setting of a Strategy of Early Coronarography to Patients With an Acute Coronary Syndrome Without ST Elevation [NCT00445263]Phase 4170 participants (Actual)Interventional2007-03-31Terminated(stopped due to Because of inclusion delay)
Safety and Efficacy of Tirofiban in Preventing Neurological Deterioration of Patients With Acute Ischemic Stroke: A Randomized Controlled Trial [NCT04491695]Phase 2/Phase 3420 participants (Anticipated)Interventional2020-09-12Recruiting
The Effect Of Antiplatelets Therapy, Tirafiban, Prasugrel, And Aspirin On Saphenous Vein Coronary Artery Bypass Graft Patency [NCT01598337]Phase 3200 participants (Anticipated)Interventional2011-04-30Recruiting
Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention [NCT03048019]10 participants (Actual)Observational2017-08-23Terminated(stopped due to study terminated per PI)
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention [NCT03114995]Phase 4140 participants (Actual)Interventional2012-02-01Completed
Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients [NCT03078257]Phase 190 participants (Anticipated)Interventional2016-01-01Recruiting
Safety and Efficacy of Tirofiban in Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy-A Prospective, Randomized, Controlled, Open-Label, Assessor-Blind, Multicenter Clinical Study [NCT04851457]Phase 2/Phase 3200 participants (Anticipated)Interventional2021-05-31Not yet recruiting
A Pilot, Exploratory Clinical Trial to Evaluate the Safety of Using Continuous IV Infusion of Tirofiban (24 Hours) Including Its Efficacy in Improving Perfusion Post Mechanical Thrombectomy in Acute Ischemic Stroke [NCT04818944]Phase 1/Phase 20 participants (Actual)Interventional2023-03-01Withdrawn(stopped due to PI has left the Institution)
A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary [NCT00251576]Phase 34,497 participants (Actual)Interventional1999-11-01Completed
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction: A Randomized, Double-blinded, Placebo-controlled, Multi-center Trial [NCT05310968]Phase 4970 participants (Anticipated)Interventional2022-11-30Recruiting
Prevention of Coronary Slow Flow or No-Reflow During Primary Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction [NCT03406819]1,000 participants (Anticipated)Interventional2018-01-07Recruiting
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Early Administration of Tirofiban in Acute Ischemic Stroke Patients Treated With Intravenous Alteplase Thrombolysis [NCT03357133]Phase 2/Phase 330 participants (Actual)Interventional2017-12-16Terminated(stopped due to The number and speed of enrollment were significantly less than expected.)
Efficacy of Simultaneous Infusion of Tirofiban With Intravenous Thrombolysis in Patients With Acute Anterior Choroidal Infarction or Paramedian Pontine Infarction [NCT05733507]48 participants (Actual)Observational2023-04-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00445263 (1) [back to overview]Mortality, Myocardial Infarction and Revascularization in Emergency
NCT01103440 (2) [back to overview]Number of Participants With Elevation of Cardiac Enzyme
NCT01103440 (2) [back to overview]Number of Participants With Major Adverse Cardiac Event (MACE)
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (≥ 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding
NCT01522417 (5) [back to overview]The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization
NCT01522417 (5) [back to overview]Individual Components of Death, Urgent Target Revascularization or Major Bleeding
NCT01522417 (5) [back to overview]Individual Components of Periprocedural Myonecrosis
NCT03048019 (4) [back to overview]Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%)
NCT03048019 (4) [back to overview]Shear-induced Thrombus Formation (AUC)
NCT03048019 (4) [back to overview]Thrombin Induced Platelet-fibrin Clot Strength (mm)
NCT03048019 (4) [back to overview]Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%)
NCT03114995 (2) [back to overview]Area Under Curve of Serial Cardiac Biomarkers
NCT03114995 (2) [back to overview]Percentage of Participants With Periprocedural Myonecrosis
NCT03691727 (2) [back to overview]Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm
NCT03691727 (2) [back to overview]Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic)

Mortality, Myocardial Infarction and Revascularization in Emergency

(NCT00445263)
Timeframe: d30

Interventionparticipants (Number)
Early Invasive Strategy2
Delayed Invasive Strategy21

[back to top]

Number of Participants With Elevation of Cardiac Enzyme

Number of participants with peri-procedural biomarker elevation defined as any elevation above baseline of CK-MB or Tn-I within 24 hours after completion of the procedure. (NCT01103440)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Conventional Strategy4
Aggressive Strategy2

[back to top]

Number of Participants With Major Adverse Cardiac Event (MACE)

Number of participants with MACE which is any event of Death, MI, Stent Thrombosis, Urgent Revascularization, Bleeding. Major adverse cardiac events (MACE), defined as the composite of death, MI (CK-MB > 3 times normal), urgent revascularization and definite or probable stent thrombosis (ST) within 30 days. Stent thrombosis was defined according to the new academic research consortium definitions; 2) bleeding complications within 30 days. Major bleeding was defined as intracranial or intraocular bleeding or a drop in hemoglobin > 5 g/dL. Minor bleeding was defined as hemorrhage at the access site requiring intervention, hematoma with a diameter of at least 5 cm, a reduction in hemoglobin levels of at least 4 g/dL without an overt bleeding source or at least 3 g/dL with such a source, reoperation for bleeding or transfusion of a blood product. (NCT01103440)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Conventional Strategy5
Aggressive Strategy1

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (≥ 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 10 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)36
Eptifibatide (Integrilin)35
Long Tirofiban (Aggrastat)32

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)69
Eptifibatide (Integrilin)60
Long Tirofiban (Aggrastat)48

[back to top]

The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization

The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), or urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

InterventionParticipants (Count of Participants)
Short Tirofiban (Aggrastat)69
Eptifibatide (Integrilin)60
Long Tirofiban (Aggrastat)45

[back to top]

Individual Components of Death, Urgent Target Revascularization or Major Bleeding

Individual components of death (any-cause), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 major bleeding criteria. (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

,,
InterventionParticipants (Count of Participants)
DeathuTVRREPLACE-2 Major Bleeding
Eptifibatide (Integrilin)101
Long Tirofiban (Aggrastat)014
Short Tirofiban (Aggrastat)010

[back to top]

Individual Components of Periprocedural Myonecrosis

Individual components of periprocedural myonecrosis (PPM) (defined as ≥ 3 times, ≥ 10 times, ≥ 20 times or ≥ 50 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value) (NCT01522417)
Timeframe: 48 hours or hospital discharge, whichever came first

,,
InterventionParticipants (Count of Participants)
≥ 3 times ULN≥ 10 times ULN≥ 20 times ULN≥ 50 times ULN
Eptifibatide (Integrilin)60352719
Long Tirofiban (Aggrastat)4528219
Short Tirofiban (Aggrastat)69361911

[back to top]

Adenosine Diphosphate (ADP) Induced Platelet Aggregation (%)

Assessment of platelet aggregation (%) in response to 20uM ADP at baseline and serially following tirofiban or cangrelor infusion. Normal reference range is 60-100% aggregation. (NCT03048019)
Timeframe: 30 minutes post-start of the infusion

Intervention% aggregation (Mean)
Tirofiban Therapy3.3
Cangrelor Therapy39.4

[back to top]

Shear-induced Thrombus Formation (AUC)

Real time evaluation of shear-induced thrombus formation using novel RUO T-TAS plus system. AUC is calculated as time to reach 60 kPa (NCT03048019)
Timeframe: 30 minutes after the end of the infusion.

InterventionkPa*min (Mean)
Tirofiban Therapy14.1
Cangrelor Therapy1004

[back to top]

Thrombin Induced Platelet-fibrin Clot Strength (mm)

Assessment of thrombin induced platelet-fibrin clot strength (mm) by thromboelastography (TEG6S). Normal reference range is 55-68 mm (NCT03048019)
Timeframe: 30 minutes post-start of the infusion

Interventionmm (Mean)
Tirofiban Therapy63.9
Cangrelor Therapy62.3

[back to top]

Thrombin Receptor Activator Peptide (TRAP) Induced Platelet Aggregation (%)

Assessment of platelet aggregation (%) in response to 10uM thrombin receptor activator peptide. Normal reference range is 60-100% aggregation. (NCT03048019)
Timeframe: 30 minutes post-start of the infusion

Intervention% aggregation (Mean)
Tirofiban Therapy42.5
Cangrelor Therapy71.2

[back to top]

Area Under Curve of Serial Cardiac Biomarkers

An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionHours*ng/ml (Median)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)38.092.7
Control C2 (Low Platelet Reactivity - no Tirofiban)121.4185.6
Group A (High Platelet Reactivity - Tirofiban)197.2252.5

[back to top]

Percentage of Participants With Periprocedural Myonecrosis

"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionParticipants (Count of Participants)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)1510
Control C2 (Low Platelet Reactivity - no Tirofiban)2625
Group A (High Platelet Reactivity - Tirofiban)1611

[back to top]

Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm

The measurement of then incidence of delayed cerebral ischemia /clinical vasospasm in Tirofiban/Aggrastat group vs. placebo (NCT03691727)
Timeframe: Day 1 to Day 7

InterventionParticipants (Count of Participants)
Tirofiban Hydrochloride (AGGRASTAT®)1
Standard of Care Control Arm4

[back to top]

Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic)

The hypothesis is that the prevalence of intracranial hemorrhage (symptomatic and asymptomatic) secondary to ventriculostomy/VPS placement during the course of Aggrastat use is within 10% difference when compared to control using Day 1 and Day 7 non-contrast head CT to determine. (NCT03691727)
Timeframe: Day 1 to Day 7

InterventionParticipants (Count of Participants)
Tirofiban Hydrochloride (AGGRASTAT®)2
Standard of Care Control Arm1

[back to top]